(E/Z)-Afatinib | (E/Z)-BIBW 2992 | EGFR | HER2 | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / / (E/Z)-Afatinib

(E/Z)-Afatinib {[allProObj[0].p_purity_real_show]}

货号：A369713 同义名： (E/Z)-BIBW 2992

Afatinib is an irreversible inhibitor of pan-ErbB inhibitor with IC50 values of 0.4nM, 0.5nM, 10nM, 14nM and 1nM for EGFR (L858R), EGFR (wt), EGFR (L858R/T790M), HER2 and ErbB4, respectively.

(E/Z)-Afatinib 化学结构
CAS号：439081-18-2

(E/Z)-Afatinib 3D分子结构
CAS号：439081-18-2

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

(E/Z)-Afatinib 纯度/质量文件产品仅供科研

货号：A369713 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: 更多 >

EGFR 亚型比较
HER2 亚型比较

产品名称	EGFR/ErbB1 ↓ ↑	ErbB3 ↓ ↑	ErbB4 ↓ ↑	HER2/ErbB2 ↓ ↑	mutant EGFR ↓ ↑	其他靶点	纯度
WZ-3146	++++ EGFR (E746_A750), IC50: 2 nM EGFR (E746_A750/T790M), IC50: 14 nM						99%+
Daphnetin	+ EGFR, IC50: 7.67 μM					PKC,PKA	95%
Lifirafenib	++ EGFR, IC50: 29 nM				+ EGFR(T790M/L858R), IC50: 495 nM		98%
PD168393	++++ EGFR, IC50: 0.70 nM						99%+
Nazartinib	++ mutant EGFR, Ki: 0.031 μM				++ mutant EGFR, Ki: 0.031 μM		98%
Norcantharidin	✔						98%
CL-387785	++++ EGFR, IC50: 370 pM						98%
WHI-P154	+++ EGFR, IC50: 4 nM					VEGFR,Src	98%
Tyrphostin A9	+ EGFR, IC50: 460 μM					PDGFR	98%
AG 555	+ EGFR, IC50: 0.7 μM						98%
AG 494	+ EGFR, IC50: 1.2 μM						99%+
AG-556	+ EGFR, IC50: 5 μM						98%
RG13022	+ EGFR, IC50: 4 μM						99%+
Tyrphostin RG 14620	✔						99%+
Vandetanib	+ EGFR, IC50: 500 nM						99%
CNX-2006	++ mutant EGFR, IC50: <20 nM				++ mutant EGFR, IC50: <20 nM		99%
AZD3759	++++ EGFR (WT), IC50: 0.3 nM EGFR (L858R), IC50: 0.2 nM						98%
Erlotinib	++++ EGFR, IC50: 2 nM						95%
Saracatinib	+++ EGFR, IC50: 5 nM EGFR (L861Q), IC50: 4 nM						99%+
AG1557	✔						99%
Rociletinib	++ EGFR (L858R/T790M), Ki: 21.5 nM EGFR (wt), Ki: 303.3 nM						98%
AG490	+ EGFR, IC50: 0.1 μM						98%
Cetuximab	++++ EGFR, Kd: 0.39 nM						99%
Osimertinib	++ WT EGFR, IC50: 12.92 nM L858R/T790M EGFR, IC50: 11.44 nM						98%
Osimertinib mesylate	✔						98% (Content MsOH 15.2-18.2%)
Chrysophanol	✔					mTOR	98%
PD153035	++++ EGFR, Ki: 5.2 pM						99%+
Olmutinib	✔					BTK	99%+
WZ4002	++++ EGFR (L858R), IC50: 2 nM EGFR (L858R/T790M), IC50: 8 nM						99%+
Icotinib	+++ EGFR, IC50: 5 nM						99%
Desmethyl Erlotinib HCl	++++ EGFR, IC50: 2 nM						99%
Cyasterone	✔						99%+
PP 3	+ EGFR tyrosine kinase, IC50: 2.7 μM						98%
WZ8040	✔						99%+
(-)-Epigallocatechin Gallate	✔						99%
AG 18	+ EGFR, IC50: 35 μM						99%+
O-Desmethyl gefitinib	++ EGFR, IC50: 36 nM						99%
Falnidamol	✔						99%+
AZ-5104	++++ EGFR (L858R), IC50: 6 nM EGFR (L861Q) , IC50: <1 nM		+++ ErbB4, IC50: 7 nM			BRK	99%+
Butein	✔						95%
Genistein	✔						98%
SU5214	+ EGFR, IC50: 36.7 μM						99%+
Naquotinib	✔						99%+
Gefitinib	++ EGFR, IC50: 15.5 nM				+ EGFR (858R/T790M), IC50: 823.3 nM		98%
Theliatinib	+++ WT EGFR, IC50: 3 nM				++ EGFR T790M/L858R, IC50: 22 nM		99%
Lazertinib	++++ WT EGFR, IC50: 76 nM L858R/T790M EGFR, IC50: 2 nM				++++ Del19/T790M, IC50: 1.7 nM		99%+
Gefitinib-based PROTAC 3	++ EGFR, DC50: 22.3 nM						99%+
MTX-211	✔					PI3K	98%
(E)-AG 99	✔						99%+
Licochalcone D	✔					PARP,Caspase	99%
Zipalertinib	+++ EGFR WT, IC50: 8 nM EGFR (L861Q), IC50: 4.1 nM		+++ HER4, IC50: 4 nM		++++ EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM		97%
JND3229	+++ EGFR WT, IC50: 6.8 nM				++ EGFR L858R/T790M, IC50: 30.5 nM		99%+
Firmonertinib mesylate	✔						99%+
Tyrphostin AG30	✔						99%+
EGFR-IN-12	++ EGFR, IC50: 21 nM						99%+
Mobocertinib	✔						98%
(Rac)-JBJ-04-125-02	✔						99%
(S)-Sunvozertinib	✔						99%
BLU-945	✔						95%
Poziotinib	+++ HER1, IC50: 3.2 nM		++ HER4, IC50: 23.5 nM	+++ HER2, IC50: 5.3 nM			98%
TAK-285	++ EGFR/HER1, IC50: 23 nM		+ HER4, IC50: 260 nM	++ HER2, IC50: 17 nM			99%+
ARRY-380 analog				✔			99%
Canertinib	++++ EGFR, IC50: 1.5 nM			+++ ErbB2, IC50: 9.0 nM			99%+
Dacomitinib	+++ EGFR, IC50: 6.0 nM		+ ErbB4, IC50: 73.7 nM	+ ErbB2, IC50: 45.7 nM			98%
EGFR/ErbB-2/ErbB-4 inhibitor-2			+ ErbB4, IC50: 1.91 μM	+ ErbB2, IC50: 0.08 μM			99%+
(E/Z)-CP-724714				++ HER2/ErbB2, IC50: 10 nM			95%
Lapatinib	++ EGFR, IC50: 10.8 nM		+ ErbB4, IC50: 367 nM	+++ ErbB2, IC50: 9.2 nM			98%
AEE788	++++ EGFR, IC50: 2 nM		+ HER4/ErbB4, IC50: 160 nM	+++ HER2/ErbB2, IC50: 6 nM		c-Fms	98+%
AV-412 free base	++++ EGFR, IC50: 0.75 nM			++ ErbB2, IC50: 19 nM	++++ EGFR^L858R/T790M, IC50: 0.51 nM EGFR^T790M, IC50: 0.79 nM		98+%
Neratinib	+ EGFR, IC50: 92 nM			+ HER2, IC50: 59 nM		Src	98%
BMS-599626	++ HER1, IC50: 20 nM		+ HER4, IC50: 190 nM	++ HER2, IC50: 30 nM			98%
Tucatinib				+++ ErbB2, IC50: 8 nM			98%
Allitinib	++++ EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Pelitinib	+ EGFR, IC50: 38.5 nM			+ ErbB2, IC50: 1.255 μM		Src,Raf	99%+
Sapitinib	+++ EGFR, IC50: 4 nM	+++ ErbB3, IC50: 4 nM		+++ ErbB2, IC50: 3 nM			99%+
CUDC-101	+++ EGFR, IC50: 2.4 nM			++ HER2, IC50: 15.7 nM		HDAC	99%+
Varlitinib	+++ ErbB1, IC50: 7 nM			++++ ErbB2, IC50: 2 nM			99%+
Afatinib dimaleate	++++ EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM			++ HER2, IC50: 14 nM			98%
Canertinib 2HCl	+++ EGFR, IC50: 7.4 nM			+++ ErbB2, IC50: 9 nM			99%
Allitinib tosylate	++++ EGFR (T790M/L858R), IC50: 12 nM EGFR, IC50: 0.5 nM		++++ ErbB4, IC50: 0.8 nM	+++ ErbB2, IC50: 3.0 nM			99%
Tyrphostin AG 528	+ EGFR, IC50: 4.9 μM			+ HER2, IC50: 2.1 μM			97%
Afatinib	++++ EGFR (L858R), IC50: 10 nM EGFR (wt), IC50: 0.5 nM		++++ ErbB4, IC50: 1 nM	++ HER2, IC50: 14 nM			99%
Pyrotinib dimaleate	++ EGFR, IC50: 0.013 μM			++ HER2, IC50: 0.038 μM			98%
Epertinib HCl	++++ EGFR, IC50: 1.48 nM		+++ HER4, IC50: 2.49 nM	+++ HER2, IC50: 7.15 nM			99%
Tuxobertinib	++++ EGFR, Kd: 0.2 nM			++++ HER2, Kd: 0.76 nM			99%
ALK-IN-1					++ EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM	ALK	99%
Brigatinib					+ EGFR(C797S/T790M/del19), IC50: 67.2 nM EGFR(del19), IC50: 39.9 nM	ALK,FLT3	98%
Avitinib					++++ EGFR L858R/T790M, IC50: 0.18 nM	BTK	99%+
EAI045					✔		97%
Almonertinib					✔		99%
BI-4020					++++ EGFR^{del19 T790M C797S}, IC50: 0.2 nM		99%+
EGFR-IN-7					++++ EGFR^{d746-750/T790M/C797S}, IC50: 0.26 nM EGFR^L858R/T790M, IC50: 0.19 nM		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	HER2 ↓ ↑	其他靶点	纯度
Poziotinib	++++ HER2, IC50: 5.3 nM		98%
Tyrphostin AG 879	+ HER2-Neu, IC50: 1.0 μM		95%
TAK-285	+ HER2, IC50: 17 nM		99%+
ARRY-380 analog	✔		99%
Canertinib	+++ ErbB2, IC50: 9.0 nM	EGFR	99%+
(E/Z)-CP-724714	++ HER2/ErbB2, IC50: 10 nM		95%
Lapatinib	+++ ErbB2, IC50: 9.2 nM	EGFR	98%
AEE788	++++ HER2/ErbB2, IC50: 6 nM	EGFR	98+%
Neratinib	+ HER2, IC50: 59 nM	Src,EGFR	98%
BMS-599626	+ HER2, IC50: 30 nM		98%
Mubritinib	++++ HER2/ErbB2, IC50: 6.0 nM		99%+
Tucatinib	+++ ErbB2, IC50: 8 nM		98%
Sapitinib	++++ ErbB2, IC50: 3 nM	EGFR	99%+
CUDC-101	++ HER2, IC50: 15.7 nM	HDAC,EGFR	99%+
Afatinib dimaleate	++ HER2, IC50: 14 nM		98%
Afatinib	++ HER2, IC50: 14 nM		99%
Pertuzumab	✔		95%
Trastuzumab	✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

(E/Z)-Afatinib 生物活性

描述

EGFR (epidermal growth factor receptor) family consists of four members that belong to the ErbB lineage of proteins (ErbB1 - 4) with an external domain that binds activating ligands, such as EGF, and is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype. Upon activation, EGFR phosphorylates both the receptor itself and a variety of “effector” protein. Afatinib is an irreversible inhibitor of pan-ErbB inhibitor with IC50 values of 0.4 nM, 0.5 nM, 10 nM, 14 nM and 1 nM for EGFR (L858R), EGFR (wt), EGFR (L858R/T790M), HER2^[1] (measured by cell-free in vitro kinase assays) and ErbB4^[2], respectively. Afatinib displays potent cellular effects on both EGFR and HER2 phosphorylation in cell lines with the in vitro kinase results, as well as anchorage-independent proliferation in NIH-3T3 cells ectopically expressing EGFR mutants. Afatinib inhibited survival of human NSCLC cell lines expressing HER2 776insV (NCI-H1781) or EGFR E746_A750del (HCC827), but showed no activity toward A549 cells, which expressed wild-type EGFR and HER2, but simultaneously harboring an oncogenic Kras G12S point mutation. Daily oral treatment with Afatinib at dose of 20 mg/kg for 25 days resulted in dramatic tumor regression and downregulation of EGFR and AKT phosphorylation in A431 cells xenografted models. Also the tumor regression by Afatinib can be observed in NCI-N87 cells and H1975 cells xenografted animals^[1].

作用机制

Afatinib can form a covalent modification of the ATP-binding site in the kinase domains of EGFR (Cys 773) and HER2 (Cys 805)^[1].

(E/Z)-Afatinib 细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源
22RV1		Growth Inhibition Assay		IC50=34.1754 μM	SANGER
23132-87		Growth Inhibition Assay		IC50=0.31923 μM	SANGER
5637		Growth Inhibition Assay		IC50=1.0151 μM	SANGER
639-V		Growth Inhibition Assay		IC50=31.5243 μM	SANGER

(E/Z)-Afatinib 动物研究

Dose

Mice: 20 mg/kg^[3] (p.o.)

Administration

p.o.

Pharmacokinetics

Animal	Rats^[4]
Dose	4 mg/kg (i.v.) 8 mg/kg (p.o.)
Administration	i.v. p.o.
C_max	1620 nmol/L (i.v.) 397 nmol/L (p.o.)
T_1/2	5.22 h (i.v.) 4.54 h (p.o.)
AUC_0→∞	2920 nmol·h/L (i.v.) 2600 nmol·h/L (p.o.)
CL/F	55.3 ml/min·kg (i.v.) 108 ml/min·kg (p.o.)
V_ss/F	16.2 L/kg (i.v.) 43.6 L/kg (p.o.)
AUC_0→24h	2500 nmol·h/L (i.v.) 2540 nmol·h/L (p.o.)
V_z/F	25.0 L/kg (i.v.) 42.8 L/kg (p.o.)
MRT	4.95 h (i.v.) 6.65 h (p.o.)

(E/Z)-Afatinib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02145637	NSCLC	Phase 1	Unknown	July 2016	-
NCT01649284	-		-	-	-
NCT03054038	Non-Small Cell Lung Carcinoma	Phase 1	Recruiting	March 2021	United States, California ... 展开 >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Thomas Fok tfok@coh.org Principal Investigator: Karen Reckamp, MD Stanford Cancer Institute Recruiting Stanford, California, United States, 94035 Contact: Jordan Preiss 650-723-1002 Principal Investigator: Sukhmani Padda, MD United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 收起 <<

(E/Z)-Afatinib 参考文献

[1]Li D, Ambrogio L, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene. 2008 Aug 7;27(34):4702-11.

[2]Ferrarotto R, Gold KA, et al. Afatinib in the treatment of head and neck squamous cell carcinoma. Expert Opin Investig Drugs. 2014 Jan;23(1):135-43.

[3]Hu X, Shi S, et al. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo. Sci Rep. 2017 Jul 4;7(1):4559.

[4]Pharmacokinetics of afatinib

(E/Z)-Afatinib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.06mL

0.41mL

0.21mL

10.29mL

2.06mL

1.03mL

20.58mL

4.12mL

2.06mL

(E/Z)-Afatinib 技术信息

CAS号	439081-18-2
分子式	C₂₄H₂₅ClFN₅O₃
分子量	485.93
SMILES Code	O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)C=CCN(C)C
MDL No.	MFCD12407405

别名	(E/Z)-BIBW 2992
运输	蓝冰
InChI Key	ULXXDDBFHOBEHA-CWDCEQMOSA-N
Pubchem ID	10184653

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

溶解方案

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

22RV1	Growth Inhibition Assay	IC50=34.1754 μM	SANGER
23132-87	Growth Inhibition Assay	IC50=0.31923 μM	SANGER
5637	Growth Inhibition Assay	IC50=1.0151 μM	SANGER
639-V	Growth Inhibition Assay	IC50=31.5243 μM	SANGER
647-V	Growth Inhibition Assay	IC50=3.98452 μM	SANGER
697	Growth Inhibition Assay	IC50=28.6331 μM	SANGER
769-P	Growth Inhibition Assay	IC50=2.29037 μM	SANGER
786-0	Growth Inhibition Assay	IC50=3.06408 μM	SANGER
8305C	Growth Inhibition Assay	IC50=3.75911 μM	SANGER
8505C	Growth Inhibition Assay	IC50=13.2067 μM	SANGER
8-MG-BA	Growth Inhibition Assay	IC50=36.9483 μM	SANGER
A101D	Growth Inhibition Assay	IC50=49.9425 μM	SANGER
A172	Growth Inhibition Assay	IC50=12.0798 μM	SANGER
A204	Growth Inhibition Assay	IC50=32.5069 μM	SANGER
A2058	Growth Inhibition Assay	IC50=15.0409 μM	SANGER
A2780	Growth Inhibition Assay	IC50=2.06294 μM	SANGER
A388	Growth Inhibition Assay	IC50=0.36857 μM	SANGER
A3-KAW	Growth Inhibition Assay	IC50=23.1003 μM	SANGER
A427	Growth Inhibition Assay	IC50=37.9107 μM	SANGER
A431	Growth Inhibition Assay	IC50=0.48233 μM	SANGER
A498	Growth Inhibition Assay	IC50=0.40674 μM	SANGER
A4-Fuk	Growth Inhibition Assay	IC50=22.1419 μM	SANGER
A549	Growth Inhibition Assay	IC50=6.12553 μM	SANGER
A673	Growth Inhibition Assay	IC50=41.5157 μM	SANGER
A704	Growth Inhibition Assay	IC50=18.4753 μM	SANGER
ABC-1	Growth Inhibition Assay	IC50=34.3693 μM	SANGER
ACHN	Growth Inhibition Assay	IC50=0.31994 μM	SANGER
ACN	Growth Inhibition Assay	IC50=0.55094 μM	SANGER
AGS	Growth Inhibition Assay	IC50=0.83648 μM	SANGER
ALL-PO	Growth Inhibition Assay	IC50=11.2512 μM	SANGER
AN3-CA	Growth Inhibition Assay	IC50=28.4395 μM	SANGER
AsPC-1	Growth Inhibition Assay	IC50=19.6471 μM	SANGER
ATN-1	Growth Inhibition Assay	IC50=33.1416 μM	SANGER
AU565	Growth Inhibition Assay	IC50=0.08504 μM	SANGER
BALL-1	Growth Inhibition Assay	IC50=9.21907 μM	SANGER
BB30-HNC	Growth Inhibition Assay	IC50=0.16576 μM	SANGER
BB49-HNC	Growth Inhibition Assay	IC50=43.2356 μM	SANGER
BB65-RCC	Growth Inhibition Assay	IC50=0.34593 μM	SANGER
BCPAP	Growth Inhibition Assay	IC50=27.137 μM	SANGER
BE-13	Growth Inhibition Assay	IC50=7.98112 μM	SANGER
Becker	Growth Inhibition Assay	IC50=20.7201 μM	SANGER
BEN	Growth Inhibition Assay	IC50=27.8517 μM	SANGER
BFTC-905	Growth Inhibition Assay	IC50=29.2705 μM	SANGER
BFTC-909	Growth Inhibition Assay	IC50=9.06799 μM	SANGER
BHT-101	Growth Inhibition Assay	IC50=14.241 μM	SANGER
BHY	Growth Inhibition Assay	IC50=0.28655 μM	SANGER
BPH-1	Growth Inhibition Assay	IC50=0.05988 μM	SANGER
BT-20	Growth Inhibition Assay	IC50=3.69795 μM	SANGER
BT-474	Growth Inhibition Assay	IC50=0.04986 μM	SANGER
BT-549	Growth Inhibition Assay	IC50=6.66889 μM	SANGER
BV-173	Growth Inhibition Assay	IC50=0.17596 μM	SANGER
BxPC-3	Growth Inhibition Assay	IC50=10.0972 μM	SANGER
C2BBe1	Growth Inhibition Assay	IC50=14.764 μM	SANGER
C32	Growth Inhibition Assay	IC50=9.33064 μM	SANGER
C-33-A	Growth Inhibition Assay	IC50=0.81297 μM	SANGER
C3A	Growth Inhibition Assay	IC50=30.2927 μM	SANGER
C8166	Growth Inhibition Assay	IC50=33.8854 μM	SANGER
Ca9-22	Growth Inhibition Assay	IC50=0.08353 μM	SANGER
CAKI-1	Growth Inhibition Assay	IC50=1.78211 μM	SANGER
CAL-120	Growth Inhibition Assay	IC50=15.1447 μM	SANGER
CAL-12T	Growth Inhibition Assay	IC50=1.88945 μM	SANGER
CAL-27	Growth Inhibition Assay	IC50=0.17636 μM	SANGER
CAL-33	Growth Inhibition Assay	IC50=0.20184 μM	SANGER
CAL-39	Growth Inhibition Assay	IC50=0.11792 μM	SANGER
CAL-51	Growth Inhibition Assay	IC50=31.5667 μM	SANGER
CAL-54	Growth Inhibition Assay	IC50=0.61621 μM	SANGER
CAL-62	Growth Inhibition Assay	IC50=43.4028 μM	SANGER
CAL-72	Growth Inhibition Assay	IC50=10.9391 μM	SANGER
CAL-85-1	Growth Inhibition Assay	IC50=9.87383 μM	SANGER
Calu-3	Growth Inhibition Assay	IC50=0.81434 μM	SANGER
Calu-6	Growth Inhibition Assay	IC50=30.2963 μM	SANGER
CAMA-1	Growth Inhibition Assay	IC50=9.28128 μM	SANGER
CAPAN-1	Growth Inhibition Assay	IC50=30.5181 μM	SANGER
Capan-2	Growth Inhibition Assay	IC50=3.46875 μM	SANGER
CaR-1	Growth Inhibition Assay	IC50=2.28281 μM	SANGER
CAS-1	Growth Inhibition Assay	IC50=46.7701 μM	SANGER
Ca-Ski	Growth Inhibition Assay	IC50=7.64259 μM	SANGER
CCRF-CEM	Growth Inhibition Assay	IC50=25.967 μM	SANGER
CFPAC-1	Growth Inhibition Assay	IC50=1.42493 μM	SANGER
CGTH-W-1	Growth Inhibition Assay	IC50=42.4955 μM	SANGER
ChaGo-K-1	Growth Inhibition Assay	IC50=32.007 μM	SANGER
CHL-1	Growth Inhibition Assay	IC50=0.01839 μM	SANGER
CHP-212	Growth Inhibition Assay	IC50=22.3222 μM	SANGER
COLO-320-HSR	Growth Inhibition Assay	IC50=18.746 μM	SANGER
COLO-678	Growth Inhibition Assay	IC50=0.80834 μM	SANGER
COLO-679	Growth Inhibition Assay	IC50=35.388 μM	SANGER
COLO-680N	Growth Inhibition Assay	IC50=44.339 μM	SANGER
COLO-684	Growth Inhibition Assay	IC50=16.9477 μM	SANGER
COLO-741	Growth Inhibition Assay	IC50=20.66 μM	SANGER
COLO-792	Growth Inhibition Assay	IC50=25.2732 μM	SANGER
COLO-800	Growth Inhibition Assay	IC50=7.41446 μM	SANGER
COLO-824	Growth Inhibition Assay	IC50=15.1579 μM	SANGER
COLO-829	Growth Inhibition Assay	IC50=8.80976 μM	SANGER
COR-L105	Growth Inhibition Assay	IC50=0.21084 μM	SANGER
COR-L23	Growth Inhibition Assay	IC50=24.1767 μM	SANGER
COR-L88	Growth Inhibition Assay	IC50=0.64113 μM	SANGER
CP50-MEL-B	Growth Inhibition Assay	IC50=17.0343 μM	SANGER
CP66-MEL	Growth Inhibition Assay	IC50=15.4688 μM	SANGER
CTB-1	Growth Inhibition Assay	IC50=4.8488 μM	SANGER
CTV-1	Growth Inhibition Assay	IC50=0.64392 μM	SANGER
CW-2	Growth Inhibition Assay	IC50=0.46914 μM	SANGER
D-263MG	Growth Inhibition Assay	IC50=33.8378 μM	SANGER
D-283MED	Growth Inhibition Assay	IC50=18.0088 μM	SANGER
D-336MG	Growth Inhibition Assay	IC50=30.2892 μM	SANGER
D-392MG	Growth Inhibition Assay	IC50=35.0565 μM	SANGER
D-423MG	Growth Inhibition Assay	IC50=5.61705 μM	SANGER
D-502MG	Growth Inhibition Assay	IC50=8.29282 μM	SANGER
D-542MG	Growth Inhibition Assay	IC50=1.01064 μM	SANGER
D-566MG	Growth Inhibition Assay	IC50=29.9393 μM	SANGER
Daoy	Growth Inhibition Assay	IC50=24.126 μM	SANGER
DB	Growth Inhibition Assay	IC50=7.61005 μM	SANGER
DBTRG-05MG	Growth Inhibition Assay	IC50=13.0632 μM	SANGER
DEL	Growth Inhibition Assay	IC50=10.3946 μM	SANGER
Detroit562	Growth Inhibition Assay	IC50=1.70152 μM	SANGER
DJM-1	Growth Inhibition Assay	IC50=6.92012 μM	SANGER
DK-MG	Growth Inhibition Assay	IC50=30.5456 μM	SANGER
DMS-114	Growth Inhibition Assay	IC50=40.8374 μM	SANGER
DMS-273	Growth Inhibition Assay	IC50=32.5322 μM	SANGER
DMS-79	Growth Inhibition Assay	IC50=40.5889 μM	SANGER
DOHH-2	Growth Inhibition Assay	IC50=20.5463 μM	SANGER
DOK	Growth Inhibition Assay	IC50=0.03194 μM	SANGER
DoTc2-4510	Growth Inhibition Assay	IC50=0.32219 μM	SANGER
DSH1	Growth Inhibition Assay	IC50=0.03314 μM	SANGER
DU-145	Growth Inhibition Assay	IC50=0.44833 μM	SANGER
DU-4475	Growth Inhibition Assay	IC50=1.40121 μM	SANGER
ECC10	Growth Inhibition Assay	IC50=1.55369 μM	SANGER
EC-GI-10	Growth Inhibition Assay	IC50=0.05912 μM	SANGER
EFM-19	Growth Inhibition Assay	IC50=37.7967 μM	SANGER
EFO-21	Growth Inhibition Assay	IC50=11.1045 μM	SANGER
EFO-27	Growth Inhibition Assay	IC50=0.05182 μM	SANGER
EGI-1	Growth Inhibition Assay	IC50=28.5928 μM	SANGER
EKVX	Growth Inhibition Assay	IC50=1.01064 μM	SANGER
EM-2	Growth Inhibition Assay	IC50=14.8576 μM	SANGER
EoL-1-cell	Growth Inhibition Assay	IC50=0.26892 μM	SANGER
EPLC-272H	Growth Inhibition Assay	IC50=4.41533 μM	SANGER
ES1	Growth Inhibition Assay	IC50=19.9213 μM	SANGER
ES3	Growth Inhibition Assay	IC50=16.9134 μM	SANGER
ES4	Growth Inhibition Assay	IC50=0.97836 μM	SANGER
ES5	Growth Inhibition Assay	IC50=4.83723 μM	SANGER
ES7	Growth Inhibition Assay	IC50=19.6292 μM	SANGER
ES8	Growth Inhibition Assay	IC50=17.6087 μM	SANGER
ESS-1	Growth Inhibition Assay	IC50=18.5205 μM	SANGER
ETK-1	Growth Inhibition Assay	IC50=1.37456 μM	SANGER
EW-1	Growth Inhibition Assay	IC50=45.9689 μM	SANGER
EW-11	Growth Inhibition Assay	IC50=9.17653 μM	SANGER
EW-13	Growth Inhibition Assay	IC50=14.0352 μM	SANGER
EW-16	Growth Inhibition Assay	IC50=27.2947 μM	SANGER
EW-18	Growth Inhibition Assay	IC50=0.68698 μM	SANGER
EW-22	Growth Inhibition Assay	IC50=41.8697 μM	SANGER
EW-24	Growth Inhibition Assay	IC50=21.3945 μM	SANGER
EW-3	Growth Inhibition Assay	IC50=1.07883 μM	SANGER
FADU	Growth Inhibition Assay	IC50=0.54404 μM	SANGER
FTC-133	Growth Inhibition Assay	IC50=11.1407 μM	SANGER
G-361	Growth Inhibition Assay	IC50=26.1027 μM	SANGER
G-401	Growth Inhibition Assay	IC50=1.67413 μM	SANGER
G-402	Growth Inhibition Assay	IC50=35.9867 μM	SANGER
GAK	Growth Inhibition Assay	IC50=25.2963 μM	SANGER
GAMG	Growth Inhibition Assay	IC50=3.91314 μM	SANGER
GB-1	Growth Inhibition Assay	IC50=25.4069 μM	SANGER
GCIY	Growth Inhibition Assay	IC50=1.08104 μM	SANGER
GCT	Growth Inhibition Assay	IC50=20.3026 μM	SANGER
GI-1	Growth Inhibition Assay	IC50=22.7658 μM	SANGER
GI-ME-N	Growth Inhibition Assay	IC50=31.0571 μM	SANGER
GMS-10	Growth Inhibition Assay	IC50=2.03517 μM	SANGER
GOTO	Growth Inhibition Assay	IC50=31.8506 μM	SANGER
GP5d	Growth Inhibition Assay	IC50=6.97394 μM	SANGER
GR-ST	Growth Inhibition Assay	IC50=28.6696 μM	SANGER
GT3TKB	Growth Inhibition Assay	IC50=8.67964 μM	SANGER
H9	Growth Inhibition Assay	IC50=0.07132 μM	SANGER
HAL-01	Growth Inhibition Assay	IC50=8.5191 μM	SANGER
HC-1	Growth Inhibition Assay	IC50=5.51839 μM	SANGER
HCC1187	Growth Inhibition Assay	IC50=20.6734 μM	SANGER
HCC1395	Growth Inhibition Assay	IC50=14.9338 μM	SANGER
HCC1419	Growth Inhibition Assay	IC50=0.36408 μM	SANGER
HCC1569	Growth Inhibition Assay	IC50=2.58297 μM	SANGER
HCC1806	Growth Inhibition Assay	IC50=0.69666 μM	SANGER
HCC1937	Growth Inhibition Assay	IC50=12.7564 μM	SANGER
HCC1954	Growth Inhibition Assay	IC50=11.0754 μM	SANGER
HCC2218	Growth Inhibition Assay	IC50=0.00987 μM	SANGER
HCC2998	Growth Inhibition Assay	IC50=5.52615 μM	SANGER
HCC38	Growth Inhibition Assay	IC50=42.9618 μM	SANGER
HCC70	Growth Inhibition Assay	IC50=0.57661 μM	SANGER
HCE-4	Growth Inhibition Assay	IC50=9.21558 μM	SANGER
HCE-T	Growth Inhibition Assay	IC50=0.88428 μM	SANGER
HCT-116	Growth Inhibition Assay	IC50=4.41007 μM	SANGER
HCT-15	Growth Inhibition Assay	IC50=22.7441 μM	SANGER
HDLM-2	Growth Inhibition Assay	IC50=0.00572 μM	SANGER
HD-MY-Z	Growth Inhibition Assay	IC50=48.786 μM	SANGER
HEC-1	Growth Inhibition Assay	IC50=3.5895 μM	SANGER
HEL	Growth Inhibition Assay	IC50=7.71203 μM	SANGER
H-EMC-SS	Growth Inhibition Assay	IC50=32.9678 μM	SANGER
HGC-27	Growth Inhibition Assay	IC50=31.5873 μM	SANGER
HH	Growth Inhibition Assay	IC50=16.5162 μM	SANGER
HL-60	Growth Inhibition Assay	IC50=4.86611 μM	SANGER
HLE	Growth Inhibition Assay	IC50=0.35046 μM	SANGER
HN	Growth Inhibition Assay	IC50=0.13077 μM	SANGER
HO-1-N-1	Growth Inhibition Assay	IC50=0.27853 μM	SANGER
HOP-62	Growth Inhibition Assay	IC50=11.6764 μM	SANGER
HOP-92	Growth Inhibition Assay	IC50=26.1226 μM	SANGER
HOS	Growth Inhibition Assay	IC50=39.6273 μM	SANGER
HPAF-II	Growth Inhibition Assay	IC50=41.6709 μM	SANGER
Hs-578-T	Growth Inhibition Assay	IC50=45.0294 μM	SANGER
HSC-2	Growth Inhibition Assay	IC50=0.16837 μM	SANGER
HSC-3	Growth Inhibition Assay	IC50=0.21198 μM	SANGER
HSC-4	Growth Inhibition Assay	IC50=0.01748 μM	SANGER
HT	Growth Inhibition Assay	IC50=40.6639 μM	SANGER
HT-1197	Growth Inhibition Assay	IC50=4.52669 μM	SANGER
HT-1376	Growth Inhibition Assay	IC50=1.01513 μM	SANGER
HT-144	Growth Inhibition Assay	IC50=27.4032 μM	SANGER
HT-29	Growth Inhibition Assay	IC50=3.07309 μM	SANGER
HT-3	Growth Inhibition Assay	IC50=1.28753 μM	SANGER
HT55	Growth Inhibition Assay	IC50=2.5738 μM	SANGER
HTC-C3	Growth Inhibition Assay	IC50=27.2561 μM	SANGER
HuCCT1	Growth Inhibition Assay	IC50=10.6033 μM	SANGER
HuH-7	Growth Inhibition Assay	IC50=28.4028 μM	SANGER
HuO-3N1	Growth Inhibition Assay	IC50=5.24043 μM	SANGER
HuO9	Growth Inhibition Assay	IC50=11.8774 μM	SANGER
HuP-T3	Growth Inhibition Assay	IC50=16.6576 μM	SANGER
HuP-T4	Growth Inhibition Assay	IC50=0.6976 μM	SANGER
HUTU-80	Growth Inhibition Assay	IC50=41.0569 μM	SANGER
IGR-1	Growth Inhibition Assay	IC50=28.8874 μM	SANGER
IGROV-1	Growth Inhibition Assay	IC50=0.25952 μM	SANGER
IST-MEL1	Growth Inhibition Assay	IC50=11.4559 μM	SANGER
IST-MES1	Growth Inhibition Assay	IC50=18.4428 μM	SANGER
IST-SL1	Growth Inhibition Assay	IC50=26.6591 μM	SANGER
J82	Growth Inhibition Assay	IC50=15.057 μM	SANGER
JAR	Growth Inhibition Assay	IC50=19.299 μM	SANGER
JEG-3	Growth Inhibition Assay	IC50=22.378 μM	SANGER
J-RT3-T3-5	Growth Inhibition Assay	IC50=6.869 μM	SANGER
JVM-2	Growth Inhibition Assay	IC50=0.88299 μM	SANGER
JVM-3	Growth Inhibition Assay	IC50=7.89599 μM	SANGER
K5	Growth Inhibition Assay	IC50=1.58357 μM	SANGER
KALS-1	Growth Inhibition Assay	IC50=23.1414 μM	SANGER
KARPAS-299	Growth Inhibition Assay	IC50=20.3422 μM	SANGER
KARPAS-45	Growth Inhibition Assay	IC50=0.01671 μM	SANGER
KASUMI-1	Growth Inhibition Assay	IC50=0.00911 μM	SANGER
KE-37	Growth Inhibition Assay	IC50=25.7315 μM	SANGER
KG-1	Growth Inhibition Assay	IC50=24.1928 μM	SANGER
KGN	Growth Inhibition Assay	IC50=32.633 μM	SANGER
KINGS-1	Growth Inhibition Assay	IC50=5.60944 μM	SANGER
KLE	Growth Inhibition Assay	IC50=4.40819 μM	SANGER
KM12	Growth Inhibition Assay	IC50=22.356 μM	SANGER
KM-H2	Growth Inhibition Assay	IC50=34.1779 μM	SANGER
KMOE-2	Growth Inhibition Assay	IC50=19.2242 μM	SANGER
KNS-42	Growth Inhibition Assay	IC50=35.5826 μM	SANGER
KNS-62	Growth Inhibition Assay	IC50=3.94731 μM	SANGER
KNS-81-FD	Growth Inhibition Assay	IC50=19.5468 μM	SANGER
KOSC-2	Growth Inhibition Assay	IC50=3.83451 μM	SANGER
KP-4	Growth Inhibition Assay	IC50=42.8832 μM	SANGER
KP-N-YN	Growth Inhibition Assay	IC50=37.6195 μM	SANGER
KP-N-YS	Growth Inhibition Assay	IC50=40.6768 μM	SANGER
KS-1	Growth Inhibition Assay	IC50=4.50889 μM	SANGER
KU-19-19	Growth Inhibition Assay	IC50=0.77464 μM	SANGER
KU812	Growth Inhibition Assay	IC50=0.15456 μM	SANGER
KURAMOCHI	Growth Inhibition Assay	IC50=7.94811 μM	SANGER
KY821	Growth Inhibition Assay	IC50=0.0206 μM	SANGER
KYSE-140	Growth Inhibition Assay	IC50=0.0833 μM	SANGER
KYSE-150	Growth Inhibition Assay	IC50=42.1782 μM	SANGER
KYSE-180	Growth Inhibition Assay	IC50=0.39089 μM	SANGER
KYSE-270	Growth Inhibition Assay	IC50=2.02732 μM	SANGER
KYSE-410	Growth Inhibition Assay	IC50=1.65672 μM	SANGER
KYSE-450	Growth Inhibition Assay	IC50=0.05978 μM	SANGER
KYSE-510	Growth Inhibition Assay	IC50=19.8748 μM	SANGER
KYSE-520	Growth Inhibition Assay	IC50=5.20839 μM	SANGER
KYSE-70	Growth Inhibition Assay	IC50=30.5114 μM	SANGER
L-363	Growth Inhibition Assay	IC50=16.4577 μM	SANGER
L-428	Growth Inhibition Assay	IC50=24.5791 μM	SANGER
LAMA-84	Growth Inhibition Assay	IC50=4.1702 μM	SANGER
LAN-6	Growth Inhibition Assay	IC50=40.0112 μM	SANGER
LB1047-RCC	Growth Inhibition Assay	IC50=2.74888 μM	SANGER
LB2241-RCC	Growth Inhibition Assay	IC50=0.10884 μM	SANGER
LB2518-MEL	Growth Inhibition Assay	IC50=49.8723 μM	SANGER
LB373-MEL-D	Growth Inhibition Assay	IC50=7.76771 μM	SANGER
LB771-HNC	Growth Inhibition Assay	IC50=35.1658 μM	SANGER
LB831-BLC	Growth Inhibition Assay	IC50=38.6039 μM	SANGER
LC-2-ad	Growth Inhibition Assay	IC50=21.2729 μM	SANGER
LCLC-103H	Growth Inhibition Assay	IC50=36.7803 μM	SANGER
LCLC-97TM1	Growth Inhibition Assay	IC50=4.53686 μM	SANGER
LK-2	Growth Inhibition Assay	IC50=13.7639 μM	SANGER
LN-405	Growth Inhibition Assay	IC50=22.5913 μM	SANGER
LNCaP-Clone-FGC	Growth Inhibition Assay	IC50=15.4248 μM	SANGER
LoVo	Growth Inhibition Assay	IC50=2.10797 μM	SANGER
LOXIMVI	Growth Inhibition Assay	IC50=5.63873 μM	SANGER
LS-1034	Growth Inhibition Assay	IC50=6.20706 μM	SANGER
LS-123	Growth Inhibition Assay	IC50=3.74284 μM	SANGER
LS-411N	Growth Inhibition Assay	IC50=5.79441 μM	SANGER
LS-513	Growth Inhibition Assay	IC50=4.31217 μM	SANGER
LU-134-A	Growth Inhibition Assay	IC50=21.1026 μM	SANGER
LU-135	Growth Inhibition Assay	IC50=33.8829 μM	SANGER
LU-139	Growth Inhibition Assay	IC50=0.3051 μM	SANGER
LU-65	Growth Inhibition Assay	IC50=0.12633 μM	SANGER
LU-99A	Growth Inhibition Assay	IC50=37.5731 μM	SANGER
LXF-289	Growth Inhibition Assay	IC50=2.63565 μM	SANGER
M14	Growth Inhibition Assay	IC50=44.1332 μM	SANGER
MC116	Growth Inhibition Assay	IC50=3.95489 μM	SANGER
MCF7	Growth Inhibition Assay	IC50=16.4723 μM	SANGER
MC-IXC	Growth Inhibition Assay	IC50=11.6728 μM	SANGER
MDA-MB-157	Growth Inhibition Assay	IC50=2.21828 μM	SANGER
MDA-MB-175-VII	Growth Inhibition Assay	IC50=0.03416 μM	SANGER
MDA-MB-231	Growth Inhibition Assay	IC50=28.2795 μM	SANGER
MDA-MB-361	Growth Inhibition Assay	IC50=0.72662 μM	SANGER
MDA-MB-415	Growth Inhibition Assay	IC50=23.9499 μM	SANGER
MDA-MB-453	Growth Inhibition Assay	IC50=11.9515 μM	SANGER
ME-180	Growth Inhibition Assay	IC50=1.61096 μM	SANGER
MEG-01	Growth Inhibition Assay	IC50=4.99403 μM	SANGER
MEL-HO	Growth Inhibition Assay	IC50=30.1423 μM	SANGER
Mewo	Growth Inhibition Assay	IC50=34.1349 μM	SANGER
MFE-280	Growth Inhibition Assay	IC50=16.0488 μM	SANGER
MFH-ino	Growth Inhibition Assay	IC50=37.3371 μM	SANGER
MFM-223	Growth Inhibition Assay	IC50=16.3965 μM	SANGER
MG-63	Growth Inhibition Assay	IC50=5.48762 μM	SANGER
MHH-ES-1	Growth Inhibition Assay	IC50=27.4447 μM	SANGER
MHH-NB-11	Growth Inhibition Assay	IC50=16.0839 μM	SANGER
MHH-PREB-1	Growth Inhibition Assay	IC50=10.1999 μM	SANGER
MIA-PaCa-2	Growth Inhibition Assay	IC50=28.7959 μM	SANGER
MKN1	Growth Inhibition Assay	IC50=3.47108 μM	SANGER
MKN28	Growth Inhibition Assay	IC50=32.7838 μM	SANGER
MKN45	Growth Inhibition Assay	IC50=21.1551 μM	SANGER
MKN7	Growth Inhibition Assay	IC50=2.35335 μM	SANGER
ML-2	Growth Inhibition Assay	IC50=0.24802 μM	SANGER
MLMA	Growth Inhibition Assay	IC50=22.747 μM	SANGER
MMAC-SF	Growth Inhibition Assay	IC50=19.2607 μM	SANGER
MN-60	Growth Inhibition Assay	IC50=7.28089 μM	SANGER
MOLT-13	Growth Inhibition Assay	IC50=0.23975 μM	SANGER
MOLT-16	Growth Inhibition Assay	IC50=17.8934 μM	SANGER
MOLT-4	Growth Inhibition Assay	IC50=7.02135 μM	SANGER
Mo-T	Growth Inhibition Assay	IC50=18.8204 μM	SANGER
MPP-89	Growth Inhibition Assay	IC50=22.8661 μM	SANGER
MS-1	Growth Inhibition Assay	IC50=30.8889 μM	SANGER
MSTO-211H	Growth Inhibition Assay	IC50=45.9482 μM	SANGER
MV-4-11	Growth Inhibition Assay	IC50=3.87994 μM	SANGER
MZ1-PC	Growth Inhibition Assay	IC50=30.393 μM	SANGER
MZ2-MEL	Growth Inhibition Assay	IC50=16.8403 μM	SANGER
MZ7-mel	Growth Inhibition Assay	IC50=34.6487 μM	SANGER
NB10	Growth Inhibition Assay	IC50=22.2371 μM	SANGER
NB12	Growth Inhibition Assay	IC50=25.2947 μM	SANGER
NB13	Growth Inhibition Assay	IC50=42.6217 μM	SANGER
NB14	Growth Inhibition Assay	IC50=6.43836 μM	SANGER
NB17	Growth Inhibition Assay	IC50=31.5185 μM	SANGER
NB5	Growth Inhibition Assay	IC50=1.41317 μM	SANGER
NB69	Growth Inhibition Assay	IC50=1.02945 μM	SANGER
NB7	Growth Inhibition Assay	IC50=2.29676 μM	SANGER
NBsusSR	Growth Inhibition Assay	IC50=3.18254 μM	SANGER
NCI-H1048	Growth Inhibition Assay	IC50=2.49158 μM	SANGER
NCI-H1092	Growth Inhibition Assay	IC50=16.8316 μM	SANGER
NCI-H1155	Growth Inhibition Assay	IC50=19.7238 μM	SANGER
NCI-H1299	Growth Inhibition Assay	IC50=6.63171 μM	SANGER
NCI-H1304	Growth Inhibition Assay	IC50=26.9108 μM	SANGER
NCI-H1355	Growth Inhibition Assay	IC50=34.3889 μM	SANGER
NCI-H1395	Growth Inhibition Assay	IC50=20.6697 μM	SANGER
NCI-H1437	Growth Inhibition Assay	IC50=18.1641 μM	SANGER
NCI-H1563	Growth Inhibition Assay	IC50=9.76031 μM	SANGER
NCI-H1573	Growth Inhibition Assay	IC50=0.7363 μM	SANGER
NCI-H1581	Growth Inhibition Assay	IC50=29.3145 μM	SANGER
NCI-H1623	Growth Inhibition Assay	IC50=0.08025 μM	SANGER
NCI-H1648	Growth Inhibition Assay	IC50=0.44182 μM	SANGER
NCI-H1650	Growth Inhibition Assay	IC50=9.60946 μM	SANGER
NCI-H1651	Growth Inhibition Assay	IC50=25.597 μM	SANGER
NCI-H1666	Growth Inhibition Assay	IC50=1.80948 μM	SANGER
NCI-H1693	Growth Inhibition Assay	IC50=3.84181 μM	SANGER
NCI-H1703	Growth Inhibition Assay	IC50=9.34375 μM	SANGER
NCI-H1755	Growth Inhibition Assay	IC50=41.8725 μM	SANGER
NCI-H1770	Growth Inhibition Assay	IC50=0.1028 μM	SANGER
NCI-H1793	Growth Inhibition Assay	IC50=14.2087 μM	SANGER
NCI-H1838	Growth Inhibition Assay	IC50=0.60299 μM	SANGER
NCI-H1975	Growth Inhibition Assay	IC50=0.61728 μM	SANGER
NCI-H1993	Growth Inhibition Assay	IC50=8.33631 μM	SANGER
NCI-H2009	Growth Inhibition Assay	IC50=3.61216 μM	SANGER
NCI-H2029	Growth Inhibition Assay	IC50=43.5581 μM	SANGER
NCI-H2030	Growth Inhibition Assay	IC50=14.6448 μM	SANGER
NCI-H2052	Growth Inhibition Assay	IC50=21.8963 μM	SANGER
NCI-H2087	Growth Inhibition Assay	IC50=49.9682 μM	SANGER
NCI-H209	Growth Inhibition Assay	IC50=0.2046 μM	SANGER
NCI-H2122	Growth Inhibition Assay	IC50=34.3471 μM	SANGER
NCI-H2126	Growth Inhibition Assay	IC50=0.51926 μM	SANGER
NCI-H2170	Growth Inhibition Assay	IC50=0.03728 μM	SANGER
NCI-H2228	Growth Inhibition Assay	IC50=32.6602 μM	SANGER
NCI-H226	Growth Inhibition Assay	IC50=49.7785 μM	SANGER
NCI-H2291	Growth Inhibition Assay	IC50=5.98943 μM	SANGER
NCI-H23	Growth Inhibition Assay	IC50=37.4196 μM	SANGER
NCI-H2342	Growth Inhibition Assay	IC50=17.557 μM	SANGER
NCI-H2405	Growth Inhibition Assay	IC50=17.1974 μM	SANGER
NCI-H28	Growth Inhibition Assay	IC50=7.16405 μM	SANGER
NCI-H292	Growth Inhibition Assay	IC50=0.0609 μM	SANGER
NCI-H358	Growth Inhibition Assay	IC50=0.5321 μM	SANGER
NCI-H441	Growth Inhibition Assay	IC50=3.59841 μM	SANGER
NCI-H446	Growth Inhibition Assay	IC50=37.4862 μM	SANGER
NCI-H460	Growth Inhibition Assay	IC50=46.523 μM	SANGER
NCI-H510A	Growth Inhibition Assay	IC50=31.4006 μM	SANGER
NCI-H520	Growth Inhibition Assay	IC50=24.8861 μM	SANGER
NCI-H526	Growth Inhibition Assay	IC50=0.07823 μM	SANGER
NCI-H596	Growth Inhibition Assay	IC50=12.0369 μM	SANGER
NCI-H630	Growth Inhibition Assay	IC50=1.45582 μM	SANGER
NCI-H650	Growth Inhibition Assay	IC50=11.2418 μM	SANGER
NCI-H661	Growth Inhibition Assay	IC50=16.9694 μM	SANGER
NCI-H69	Growth Inhibition Assay	IC50=0.21451 μM	SANGER
NCI-H720	Growth Inhibition Assay	IC50=0.05325 μM	SANGER
NCI-H727	Growth Inhibition Assay	IC50=8.1042 μM	SANGER
NCI-H747	Growth Inhibition Assay	IC50=5.42472 μM	SANGER
NCI-H810	Growth Inhibition Assay	IC50=34.7278 μM	SANGER
NCI-H82	Growth Inhibition Assay	IC50=1.54006 μM	SANGER
NCI-N87	Growth Inhibition Assay	IC50=0.02773 μM	SANGER
NCI-SNU-1	Growth Inhibition Assay	IC50=3.69735 μM	SANGER
NCI-SNU-5	Growth Inhibition Assay	IC50=1.239 μM	SANGER
NEC8	Growth Inhibition Assay	IC50=14.5472 μM	SANGER
NH-12	Growth Inhibition Assay	IC50=7.72808 μM	SANGER
NKM-1	Growth Inhibition Assay	IC50=3.18744 μM	SANGER
NMC-G1	Growth Inhibition Assay	IC50=12.9234 μM	SANGER
no-10	Growth Inhibition Assay	IC50=16.6343 μM	SANGER
no-11	Growth Inhibition Assay	IC50=3.53564 μM	SANGER
NOMO-1	Growth Inhibition Assay	IC50=34.5703 μM	SANGER
NOS-1	Growth Inhibition Assay	IC50=11.7109 μM	SANGER
NTERA-S-cl-D1	Growth Inhibition Assay	IC50=5.54537 μM	SANGER
NUGC-3	Growth Inhibition Assay	IC50=0.38373 μM	SANGER
NY	Growth Inhibition Assay	IC50=3.53655 μM	SANGER
OAW-28	Growth Inhibition Assay	IC50=7.94578 μM	SANGER
OAW-42	Growth Inhibition Assay	IC50=3.50026 μM	SANGER
OC-314	Growth Inhibition Assay	IC50=15.4714 μM	SANGER
OCI-AML2	Growth Inhibition Assay	IC50=8.95481 μM	SANGER
OCUB-M	Growth Inhibition Assay	IC50=3.76187 μM	SANGER
OE19	Growth Inhibition Assay	IC50=1.71512 μM	SANGER
OE33	Growth Inhibition Assay	IC50=13.786 μM	SANGER
OMC-1	Growth Inhibition Assay	IC50=2.08169 μM	SANGER
ONS-76	Growth Inhibition Assay	IC50=41.4709 μM	SANGER
OS-RC-2	Growth Inhibition Assay	IC50=9.0219 μM	SANGER
OVCAR-3	Growth Inhibition Assay	IC50=2.67167 μM	SANGER
OVCAR-4	Growth Inhibition Assay	IC50=10.8835 μM	SANGER
OVCAR-5	Growth Inhibition Assay	IC50=13.1593 μM	SANGER
OVCAR-8	Growth Inhibition Assay	IC50=15.8861 μM	SANGER
P12-ICHIKAWA	Growth Inhibition Assay	IC50=25.4785 μM	SANGER
P30-OHK	Growth Inhibition Assay	IC50=35.8752 μM	SANGER
PA-1	Growth Inhibition Assay	IC50=49.8335 μM	SANGER
PANC-03-27	Growth Inhibition Assay	IC50=2.16631 μM	SANGER
PANC-08-13	Growth Inhibition Assay	IC50=1.16416 μM	SANGER
PANC-10-05	Growth Inhibition Assay	IC50=14.6247 μM	SANGER
PC-14	Growth Inhibition Assay	IC50=0.05668 μM	SANGER
PC-3	Growth Inhibition Assay	IC50=19.9604 μM	SANGER
PFSK-1	Growth Inhibition Assay	IC50=13.06 μM	SANGER
QIMR-WIL	Growth Inhibition Assay	IC50=16.7105 μM	SANGER
Ramos-2G6-4C10	Growth Inhibition Assay	IC50=14.0202 μM	SANGER
RCC10RGB	Growth Inhibition Assay	IC50=18.0559 μM	SANGER
RCM-1	Growth Inhibition Assay	IC50=2.52938 μM	SANGER
RD	Growth Inhibition Assay	IC50=29.5233 μM	SANGER
RERF-LC-MS	Growth Inhibition Assay	IC50=17.5508 μM	SANGER
RH-18	Growth Inhibition Assay	IC50=18.0035 μM	SANGER
RKO	Growth Inhibition Assay	IC50=14.5075 μM	SANGER
RMG-I	Growth Inhibition Assay	IC50=7.39296 μM	SANGER
RO82-W-1	Growth Inhibition Assay	IC50=32.1604 μM	SANGER
RPMI-2650	Growth Inhibition Assay	IC50=11.5885 μM	SANGER
RPMI-7951	Growth Inhibition Assay	IC50=3.0759 μM	SANGER
RPMI-8226	Growth Inhibition Assay	IC50=4.11631 μM	SANGER
RPMI-8866	Growth Inhibition Assay	IC50=27.7562 μM	SANGER
RS4-11	Growth Inhibition Assay	IC50=12.1725 μM	SANGER
RT-112	Growth Inhibition Assay	IC50=22.8616 μM	SANGER
RVH-421	Growth Inhibition Assay	IC50=35.7645 μM	SANGER
RXF393	Growth Inhibition Assay	IC50=36.3785 μM	SANGER
S-117	Growth Inhibition Assay	IC50=36.3008 μM	SANGER
Saos-2	Growth Inhibition Assay	IC50=19.1162 μM	SANGER
SAS	Growth Inhibition Assay	IC50=0.48398 μM	SANGER
SBC-1	Growth Inhibition Assay	IC50=0.18959 μM	SANGER
SCC-15	Growth Inhibition Assay	IC50=1.39451 μM	SANGER
SCC-25	Growth Inhibition Assay	IC50=0.84171 μM	SANGER
SCC-4	Growth Inhibition Assay	IC50=8.44059 μM	SANGER
SCC-9	Growth Inhibition Assay	IC50=37.7838 μM	SANGER
SCH	Growth Inhibition Assay	IC50=18.6456 μM	SANGER
SF126	Growth Inhibition Assay	IC50=23.6924 μM	SANGER
SF268	Growth Inhibition Assay	IC50=29.5931 μM	SANGER
SF295	Growth Inhibition Assay	IC50=26.0425 μM	SANGER
SF539	Growth Inhibition Assay	IC50=9.23562 μM	SANGER
SH-4	Growth Inhibition Assay	IC50=32.1858 μM	SANGER
SHP-77	Growth Inhibition Assay	IC50=29.6182 μM	SANGER
SiHa	Growth Inhibition Assay	IC50=23.9327 μM	SANGER
SJRH30	Growth Inhibition Assay	IC50=30.2108 μM	SANGER
SJSA-1	Growth Inhibition Assay	IC50=27.0176 μM	SANGER
SKG-IIIa	Growth Inhibition Assay	IC50=3.52237 μM	SANGER
SK-HEP-1	Growth Inhibition Assay	IC50=30.6326 μM	SANGER
SK-LU-1	Growth Inhibition Assay	IC50=40.6568 μM	SANGER
SK-MEL-1	Growth Inhibition Assay	IC50=13.7135 μM	SANGER
SK-MEL-2	Growth Inhibition Assay	IC50=32.6527 μM	SANGER
SK-MEL-24	Growth Inhibition Assay	IC50=11.2366 μM	SANGER
SK-MEL-28	Growth Inhibition Assay	IC50=19.3363 μM	SANGER
SK-MEL-3	Growth Inhibition Assay	IC50=16.4787 μM	SANGER
SK-MES-1	Growth Inhibition Assay	IC50=1.11487 μM	SANGER
SK-N-AS	Growth Inhibition Assay	IC50=21.8276 μM	SANGER
SK-N-DZ	Growth Inhibition Assay	IC50=28.6885 μM	SANGER
SK-NEP-1	Growth Inhibition Assay	IC50=1.17513 μM	SANGER
SK-N-FI	Growth Inhibition Assay	IC50=28.433 μM	SANGER
SK-OV-3	Growth Inhibition Assay	IC50=8.71329 μM	SANGER
SK-PN-DW	Growth Inhibition Assay	IC50=35.4369 μM	SANGER
SK-UT-1	Growth Inhibition Assay	IC50=13.1083 μM	SANGER
SN12C	Growth Inhibition Assay	IC50=2.91964 μM	SANGER
SNU-387	Growth Inhibition Assay	IC50=40.4553 μM	SANGER
SNU-449	Growth Inhibition Assay	IC50=3.65826 μM	SANGER
SNU-C2B	Growth Inhibition Assay	IC50=2.68616 μM	SANGER
SW1116	Growth Inhibition Assay	IC50=1.01287 μM	SANGER
SW13	Growth Inhibition Assay	IC50=0.16216 μM	SANGER
SW1417	Growth Inhibition Assay	IC50=4.12147 μM	SANGER
SW1463	Growth Inhibition Assay	IC50=15.0485 μM	SANGER
SW1573	Growth Inhibition Assay	IC50=11.7295 μM	SANGER
SW1710	Growth Inhibition Assay	IC50=8.18515 μM	SANGER
SW1990	Growth Inhibition Assay	IC50=16.1755 μM	SANGER
SW48	Growth Inhibition Assay	IC50=1.25432 μM	SANGER
SW620	Growth Inhibition Assay	IC50=5.24964 μM	SANGER
SW626	Growth Inhibition Assay	IC50=11.5755 μM	SANGER
SW684	Growth Inhibition Assay	IC50=19.1326 μM	SANGER
SW756	Growth Inhibition Assay	IC50=6.91176 μM	SANGER
SW780	Growth Inhibition Assay	IC50=25.3264 μM	SANGER
SW837	Growth Inhibition Assay	IC50=12.9028 μM	SANGER
SW872	Growth Inhibition Assay	IC50=42.6331 μM	SANGER
SW900	Growth Inhibition Assay	IC50=7.82121 μM	SANGER
SW948	Growth Inhibition Assay	IC50=46.4462 μM	SANGER
SW954	Growth Inhibition Assay	IC50=1.20214 μM	SANGER
SW962	Growth Inhibition Assay	IC50=5.62032 μM	SANGER
SW982	Growth Inhibition Assay	IC50=18.2671 μM	SANGER
T-24	Growth Inhibition Assay	IC50=34.0205 μM	SANGER
T47D	Growth Inhibition Assay	IC50=3.62217 μM	SANGER
T84	Growth Inhibition Assay	IC50=11.3907 μM	SANGER
T98G	Growth Inhibition Assay	IC50=27.5846 μM	SANGER
TCCSUP	Growth Inhibition Assay	IC50=28.6418 μM	SANGER
TE-1	Growth Inhibition Assay	IC50=1.81475 μM	SANGER
TE-10	Growth Inhibition Assay	IC50=2.68078 μM	SANGER
TE-11	Growth Inhibition Assay	IC50=26.7752 μM	SANGER
TE-12	Growth Inhibition Assay	IC50=1.80414 μM	SANGER
TE-5	Growth Inhibition Assay	IC50=5.4085 μM	SANGER
TE-6	Growth Inhibition Assay	IC50=0.40246 μM	SANGER
TE-8	Growth Inhibition Assay	IC50=1.91377 μM	SANGER
TE-9	Growth Inhibition Assay	IC50=3.84382 μM	SANGER
TGBC11TKB	Growth Inhibition Assay	IC50=47.1777 μM	SANGER
TGBC1TKB	Growth Inhibition Assay	IC50=30.1238 μM	SANGER
TGBC24TKB	Growth Inhibition Assay	IC50=1.6823 μM	SANGER
TI-73	Growth Inhibition Assay	IC50=0.14715 μM	SANGER
TK10	Growth Inhibition Assay	IC50=0.26738 μM	SANGER
U031	Growth Inhibition Assay	IC50=5.25424 μM	SANGER
U-118-MG	Growth Inhibition Assay	IC50=36.8847 μM	SANGER
U251	Growth Inhibition Assay	IC50=40.4054 μM	SANGER
U-266	Growth Inhibition Assay	IC50=16.2299 μM	SANGER
U-2-OS	Growth Inhibition Assay	IC50=17.5307 μM	SANGER
U-87-MG	Growth Inhibition Assay	IC50=4.10481 μM	SANGER
UACC-257	Growth Inhibition Assay	IC50=41.7369 μM	SANGER
UACC-62	Growth Inhibition Assay	IC50=11.2368 μM	SANGER
UACC-893	Growth Inhibition Assay	IC50=0.11885 μM	SANGER
UMC-11	Growth Inhibition Assay	IC50=26.4514 μM	SANGER
UM-UC-3	Growth Inhibition Assay	IC50=9.9503 μM	SANGER
VA-ES-BJ	Growth Inhibition Assay	IC50=35.4649 μM	SANGER
VM-CUB-1	Growth Inhibition Assay	IC50=4.86819 μM	SANGER
VMRC-RCZ	Growth Inhibition Assay	IC50=8.01697 μM	SANGER
WM-115	Growth Inhibition Assay	IC50=11.7588 μM	SANGER
YAPC	Growth Inhibition Assay	IC50=11.9259 μM	SANGER
YKG-1	Growth Inhibition Assay	IC50=1.05419 μM	SANGER
ZR-75-30	Growth Inhibition Assay	IC50=0.09545 μM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02145637	NSCLC	Phase 1	Unknown	July 2016	-
NCT01649284	-		-	-	-
NCT03054038	Non-Small Cell Lung Carcinoma	Phase 1	Recruiting	March 2021	United States, California ... 展开 >> City of Hope National Medical Center Recruiting Duarte, California, United States, 91010 Contact: Thomas Fok tfok@coh.org Principal Investigator: Karen Reckamp, MD Stanford Cancer Institute Recruiting Stanford, California, United States, 94035 Contact: Jordan Preiss 650-723-1002 Principal Investigator: Sukhmani Padda, MD United States, Tennessee Vanderbilt-Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 收起 <<
NCT01085136	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	-
NCT00730925	Carcinoma, Non-Small-Cell Lung	Phase 2	Completed	-	Belgium ... 展开 >> 1200.41.32003 Boehringer Ingelheim Investigational Site Antwerpen, Belgium 1200.41.32007 Boehringer Ingelheim Investigational Site Charleroi, Belgium 1200.41.32001 Boehringer Ingelheim Investigational Site Jette, Belgium 1200.41.32011 Boehringer Ingelheim Investigational Site Leuven, Belgium 1200.41.32008 Boehringer Ingelheim Investigational Site Liège, Belgium 1200.41.32006 Boehringer Ingelheim Investigational Site Namur, Belgium Spain 1200.41.34001 Boehringer Ingelheim Investigational Site Badalona (Barcelona), Spain 收起 <<
NCT02491775	-		Terminated(Changes in treatmen... 展开 >>t plan affecting drug therapy choices) 收起 <<	-	United States, Missouri ... 展开 >> Washington University School of Medicine Saint Louis, Missouri, United States, 63110 收起 <<
NCT00525148	-		Completed	-	-
NCT01441596	Breast Neoplasms ... 展开 >> Neoplasm Metastasis 收起 <<	Phase 2	Completed	-	-
NCT01085136	-		Completed	-	-
NCT01679405	Metastatic Disease	Phase 1	Terminated(2016/04/26)	December 2016	Germany ... 展开 >> I. Medizinische Klinik und Poliklinik der Universitätsmedizin Mainz, Germany, 55131 收起 <<
NCT00525148	Carcinoma, Non-Small-Cell Lung	Phase 2	Completed	-	-
NCT01441596	-		Completed	-	-
NCT00727506	Glioma	Phase 2	Completed	-	-
NCT00730925	-		Completed	-	-
NCT01271725	Breast Neoplasms	Phase 2	Completed	-	Hong Kong ... 展开 >> 1200.98.85202 Boehringer Ingelheim Investigational Site Hong Kong, Hong Kong 1200.98.85201 Boehringer Ingelheim Investigational Site Shatin, Hong Kong India 1200.98.91011 Boehringer Ingelheim Investigational Site Amravati, India 1200.98.91009 Boehringer Ingelheim Investigational Site Maharashtra, India 1200.98.91010 Boehringer Ingelheim Investigational Site Maharashtra, India 1200.98.91004 Boehringer Ingelheim Investigational Site Nagpur, India 1200.98.91001 Boehringer Ingelheim Investigational Site Pune, India 1200.98.91005 Boehringer Ingelheim Investigational Site Thiruvananthapuram, India Poland 1200.98.48002 Boehringer Ingelheim Investigational Site Gdansk, Poland Russian Federation 1200.98.07014 Boehringer Ingelheim Investigational Site Kazan, Russian Federation 1200.98.07013 Boehringer Ingelheim Investigational Site Krasnodar, Russian Federation 1200.98.07004 Boehringer Ingelheim Investigational Site Moscow, Russian Federation 1200.98.07012 Boehringer Ingelheim Investigational Site Pyatigorsk, Russian Federation 1200.98.07008 Boehringer Ingelheim Investigational Site Samara, Russian Federation 1200.98.07011 Boehringer Ingelheim Investigational Site Sochi, Russian Federation 1200.98.07003 Boehringer Ingelheim Investigational Site Stavropol, Russian Federation 1200.98.07006 Boehringer Ingelheim Investigational Site Yaroslavl, Russian Federation Taiwan 1200.98.88603 Boehringer Ingelheim Investigational Site Taichung, Taiwan 1200.98.88607 Boehringer Ingelheim Investigational Site Taichung, Taiwan 1200.98.88601 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.98.88602 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.98.88604 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.98.88605 Boehringer Ingelheim Investigational Site Taipei, Taiwan United Kingdom 1200.98.44009 Boehringer Ingelheim Investigational Site Barnstaple, United Kingdom 1200.98.44001 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.98.44004 Boehringer Ingelheim Investigational Site Exeter, United Kingdom 1200.98.44005 Boehringer Ingelheim Investigational Site London, United Kingdom 收起 <<
NCT02372006	Neuroectodermal Tumors ... 展开 >> Rhabdomyosarcoma 收起 <<	Phase 1 Phase 2	Recruiting	August 15, 2019	-
NCT01396265	Healthy	Phase 1	Completed	-	Germany ... 展开 >> 1200.152.1 Boehringer Ingelheim Investigational Site Biberach, Germany 收起 <<
NCT01396265	-		Completed	-	-
NCT00727506	-		Completed	-	-
NCT01152437	Colorectal Neoplasms	Phase 2	Completed	-	United Kingdom ... 展开 >> 1200.74.44001 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.74.44005 Boehringer Ingelheim Investigational Site Bristol, United Kingdom 1200.74.44006 Boehringer Ingelheim Investigational Site Cambridge, United Kingdom 1200.74.44003 Boehringer Ingelheim Investigational Site Glasgow, United Kingdom 1200.74.44009 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.74.44012 Boehringer Ingelheim Investigational Site Manchester, United Kingdom 1200.74.44007 Boehringer Ingelheim Investigational Site Northwood, United Kingdom 1200.74.44013 Boehringer Ingelheim Investigational Site Nottingham, United Kingdom 1200.74.44011 Boehringer Ingelheim Investigational Site Poole, United Kingdom 1200.74.44010 Boehringer Ingelheim Investigational Site Sheffield, United Kingdom 1200.74.44008 Boehringer Ingelheim Investigational Site Southampton, United Kingdom 1200.74.44004 Boehringer Ingelheim Investigational Site Sutton, Surrey, United Kingdom 1200.74.44002 Boehringer Ingelheim Investigational Site Truro, United Kingdom 收起 <<
NCT01152437	-		Completed	-	-
NCT01426958	-		Completed	-	-
NCT01298063	Liver Diseases ... 展开 >> Healthy 收起 <<	Phase 1	Completed	-	Germany ... 展开 >> 1200.86.1 Boehringer Ingelheim Investigational Site Kiel, Germany 收起 <<
NCT02541903	Penile Squamous Cell Carcinoma... 展开 >> (PSCC) 收起 <<	Phase 2	Recruiting	October 2019	United States, Alabama ... 展开 >> University of Alabama at Birmingham Recruiting Birmingham, Alabama, United States, 35294 Contact: Pam Dixon, RN, BSN, OCN 205-975-9875 pamdixon@uab.edu Principal Investigator: Lisle Nabell, MD United States, California University of Southern California Recruiting Los Angeles, California, United States, 90033 Contact: Tanya Dorff, MD 323-865-3900 dorff@usc.edu United States, Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Cherie Perez 713-563-1602 GUClinicalTrials@mdanderson.org Principal Investigator: John Araujo, MD 收起 <<
NCT01298063	-		Completed	-	-
NCT00796549	Carcinoma, Non-Small-Cell Lung	Phase 2	Completed	-	Italy ... 展开 >> 1200.40.39011 Boehringer Ingelheim Investigational Site Arezzo, Italy 1200.40.39007 Boehringer Ingelheim Investigational Site Aviano (PN), Italy 1200.40.39013 Boehringer Ingelheim Investigational Site Faenza (RA), Italy 1200.40.39003 Boehringer Ingelheim Investigational Site Genova, Italy 1200.40.39010 Boehringer Ingelheim Investigational Site Livorno, Italy 1200.40.39012 Boehringer Ingelheim Investigational Site Lugo (RA), Italy 1200.40.39008 Boehringer Ingelheim Investigational Site Modena, Italy 1200.40.39005 Boehringer Ingelheim Investigational Site Monza (MI), Italy 1200.40.39006 Boehringer Ingelheim Investigational Site Padova, Italy 1200.40.39002 Boehringer Ingelheim Investigational Site Perugia, Italy 1200.40.39004 Boehringer Ingelheim Investigational Site Prato, Italy 1200.40.39009 Boehringer Ingelheim Investigational Site Ravenna, Italy 1200.40.39001 Boehringer Ingelheim Investigational Site Rozzano (MI), Italy 收起 <<
NCT00431067	-		Completed	-	-
NCT00796549	-		Completed	-	-
NCT00950742	Breast Neoplasms	Phase 1	Completed	-	United Kingdom ... 展开 >> 1200.68.44001 Boehringer Ingelheim Investigational Site Brighton, United Kingdom 1200.68.44003 Boehringer Ingelheim Investigational Site Cambridge, United Kingdom 1200.68.44005 Boehringer Ingelheim Investigational Site Guildford, United Kingdom 1200.68.44004 Boehringer Ingelheim Investigational Site Newcastle upon Tyne, United Kingdom 1200.68.44002 Boehringer Ingelheim Investigational Site Truro, United Kingdom 收起 <<
NCT01426958	Healthy	Phase 1	Completed	-	Germany ... 展开 >> 1200.151.1 Boehringer Ingelheim Investigational Site Biberach, Germany 收起 <<
NCT00431067	Breast Neoplasms	Phase 2	Completed	-	United States, Arizona ... 展开 >> 1200.11.3 Boehringer Ingelheim Investigational Site Scottsdale, Arizona, United States United States, California 1200.11.7 Boehringer Ingelheim Investigational Site Encinitas, California, United States 1200.11.4 Boehringer Ingelheim Investigational Site Santa Monica, California, United States United States, Florida 1200.11.2 Boehringer Ingelheim Investigational Site Tampa, Florida, United States United States, Massachusetts 1200.11.1 Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States United States, North Carolina 1200.11.5 Boehringer Ingelheim Investigational Site Chapel Hill, North Carolina, United States United Kingdom 1200.11.4401 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.11.4402 Boehringer Ingelheim Investigational Site Crownhill, Plymouth, United Kingdom 1200.11.4406 Boehringer Ingelheim Investigational Site Guildford, United Kingdom 1200.11.4405 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.11.4404 Boehringer Ingelheim Investigational Site Poole, United Kingdom 1200.11.4403 Boehringer Ingelheim Investigational Site Truro, United Kingdom 收起 <<
NCT00950742	-		Completed	-	-
NCT00875433	Neoplasms	Phase 2	Completed	-	United Kingdom ... 展开 >> 1200.24.4403 Boehringer Ingelheim Investigational Site Guildford, United Kingdom 1200.24.4402 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.24.4404 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.24.4401 Boehringer Ingelheim Investigational Site Sutton, United Kingdom 收起 <<
NCT00875433	-		Completed	-	-
NCT01931306	-		-	-	Korea, Republic of ... 展开 >> The Catholic University of Korea, Bucheon St.Mary's Hospital Bucheon, Korea, Republic of, 14647 Gachon University Gil Medical Center Incheon, Korea, Republic of, 405-760 Chonnam National University Hwasun Hospital Jeonnam, Korea, Republic of, 519-763 Gyeongsang National University Hospital Jinju, Korea, Republic of, 660-702 The Catholic University of Korea, Seoul St.Mary's Hospital Seoul, Korea, Republic of, 06591 Severance Hospital Seoul, Korea, Republic of, 120-752 Samsung Medical Center Seoul, Korea, Republic of, 135-710 SMG-SNU Boramae Medical Center Seoul, Korea, Republic of, 156-707 收起 <<
NCT00998296	Neoplasms	Phase 1	Completed	-	France ... 展开 >> 1239.14.3301A Boehringer Ingelheim Investigational Site Villejuif Cedex, France 收起 <<
NCT01251653	-		Completed	-	France ... 展开 >> 1200.93.33002 Boehringer Ingelheim Investigational Site Dijon, France 1200.93.33001 Boehringer Ingelheim Investigational Site Saint-Herblain cedex, France 1200.93.33003 Boehringer Ingelheim Investigational Site Toulouse, France 收起 <<
NCT02506517	Solid Tumors	Phase 2	Recruiting	December 2018	Canada, Ontario ... 展开 >> Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Albiruni Razak, M.D. 416-586-4800 ext 3883 Principal Investigator: Albiruni Razak, M.D. 收起 <<
NCT01647711	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	United States, Colorado ... 展开 >> Boehringer Ingelheim Investigational Site Aurora, Colorado, United States United States, Massachusetts Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States 收起 <<
NCT01649271	Breast Neoplasms ... 展开 >> Stomach Neoplasms 收起 <<	Phase 1	Completed	-	France ... 展开 >> CTR Georges-François Leclerc Dijon, France, 21079 CTR René Gauducheau, Onco, St Herblain Saint Herblain Cedex, France, 44805 INS Claudius Regaud Toulouse, France, 31059 收起 <<
NCT00998296	-		Completed	-	-
NCT02597946	Carcinoma, Non-Small-Cell Lung	Phase 2	Completed	-	China ... 展开 >> Hunan Province Tumor Hospital Changsha, China, 410013 First Affiliated Hospital of Guangzhou Medical University Guangzhou, China, 510120 Zhejiang Cancer Hospital Hangzhou, China, 310022 The Second Affiliated Hospital to Nanchang University Nanchang, China, 330006 First Hospital Affiliated with Nanjing Medical University Nanjing, China, 210029 Zhongshan Hospital Fudan University Shanghai, China, 200032 Shanghai Pulmonary Hospital Shanghai, China, 200433 Henan Cancer Hospital Zhengzhou, China, 450008 Malaysia University Malaya Medical Centre Kuala Lumpur, Malaysia, 59100 收起 <<
NCT01647711	-		Completed	-	-
NCT03157089	Carcinoma, Non-Small-Cell Lung	Phase 2	Recruiting	October 9, 2020	United States, California ... 展开 >> University of California Davis Recruiting Sacramento, California, United States, 95817 Contact: Jonathan Riess +001 (916) 734-3772 jwriess@ucdavis.edu United States, District of Columbia Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Benjamin Levy +001 (202) 660-6500 blevy11@jhmi.edu United States, Florida Florida Hospital Recruiting Orlando, Florida, United States, 32804 Contact: Tarek Mekhail +001 (407) 303-3235 tarek.mekhail.md@flhosp.org United States, Kentucky Baptist Health Medical Group Recruiting Lexington, Kentucky, United States, 40503 Contact: Firas Badin +001 (859) 276-0414 firas.badin@bhsi.com United States, Nevada Comprehensive Cancer Centers of Nevada Recruiting Las Vegas, Nevada, United States, 89128 Contact: Brian Vicuna +001 (702) 952-2140 brian.vicuna@usoncology.com United States, New York Weill Cornell Medical College Recruiting New York, New York, United States, 10021 Contact: Ronald Scheff +001 (646) 962-2066 rjs2002@med.cornell.edu United States, Washington Cancer Care Northwest Centers, PS Recruiting Spokane Valley, Washington, United States, 99216 Contact: Srivalli Gopaluni +001 (509) 228-1000 srivalli.gopaluni@ccnw.net France HOP Côte de Nacre Recruiting Caen, France, 14033 Contact: Jeannick Madelaine +33 (0)2 31 06 46 76 Madelaine-j@chu-caen.fr HOP Le Mans Recruiting Le Mans, France, 72037 Contact: Olivier Molinier +33 (0)2 43 43 24 50 omolinier@ch-lemans.fr HOP Nord Recruiting Marseille, France, 13015 Contact: Fabrice Barlesi +33 (0)4 91 38 56 28 fabrice.barlesi@ap-hm.fr HOP Nord Laënnec Recruiting Nantes, France, 44093 Contact: Jaafar Bennouna +33 (0)2 40 67 99 93 Jaafar.Bennouna@univ-nantes.fr HOP Sainte Musse Recruiting Toulon, France, 83100 Contact: Clarisse Audigier-Valette +33 (0)4 94 14 56 10 clarisse.audigier-valette@ch-toulon.fr Korea, Republic of Severance Hospital Recruiting Seoul, Korea, Republic of, 03722 Contact: Hye Ryun Kim 82 2 2228 8125 nobelg@yuhs.ac Asan Medical Center Recruiting Seoul, Korea, Republic of, 05505 Contact: Sang-We Kim 82 2 3010 3215 swkim@amc.seoul.kr Spain Hospital Vall d'Hebron Recruiting Barcelona, Spain, 08035 Contact: Enriqueta Felip +34932746077 efelip@vhio.net Complejo Hospitalario Universitario Insular - Materno Infantil Recruiting Las Palmas de Gran Canaria, Spain, 35016 Contact: Delvys Rodríguez Abreu +34928441738 drodabr@gobiernodecanarias.org Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Contact: Luis Paz-Ares Rodríguez +34913908349 lpazaresr@seom.org Hospital Clínico Universitario Lozano Blesa Recruiting Zaragoza, Spain, 50009 Contact: Dolores Isla +34976765746 lola.isla@gmail.com Turkey Hacettepe Universitesi Tip Fakultesi, Onkoloji ABD Active, not recruiting Ankara, Turkey, 06230 Istanbul Universitesi Cerrahpasa Tip Fakultesi Completed Istanbul, Turkey, 34098 收起 <<
NCT01251653	-		Completed	-	-
NCT02768337	Lung Cancer B... 展开 >>reast Cancer Brain Cancer Advanced Breast Cancer Advanced Lung Cancer 收起 <<	Phase 1 Phase 2	Recruiting	December 2021	United Kingdom ... 展开 >> Cambridge University Hospitals NHS Foundation Trust Recruiting Cambridge, England, United Kingdom, CB2 2QQ University Hospitals Birmingham NHS Foundation Trust Recruiting Birmingham, United Kingdom The Beatson West of Scotland Cancer Centre Recruiting Glasgow, United Kingdom Clatterbridge Cancer Centre Recruiting Liverpool, United Kingdom The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom Oxford University Hospitals NHS Foundation Trust Recruiting Oxford, United Kingdom 收起 <<
NCT00716417	Neoplasms	Phase 1	Completed	-	Belgium ... 展开 >> 1200.37.3202 Boehringer Ingelheim Investigational Site Bruxelles, Belgium 1200.37.3201 Boehringer Ingelheim Investigational Site Edegem, Belgium 1200.37.3203 Boehringer Ingelheim Investigational Site Gent, Belgium 收起 <<
NCT01649271	-		Completed	-	-
NCT00716417	-		Completed	-	-
NCT01156545	Non-small Cell Lung Cancer	Phase 2	Active, not recruiting	December 2019	Korea, Republic of ... 展开 >> National Cancer Center Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769 收起 <<
NCT01732640	Squamous Cell Carcinoma of the... 展开 >> Head and Neck 收起 <<	Phase 1 Phase 2	Terminated(Slow accrual and hi... 展开 >>gh levels of toxicity lead to early termination.) 收起 <<	-	United States, Maryland ... 展开 >> Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland, United States, 21287 United States, Tennessee Vanderbilt Ingram Cancer Center Nashville, Tennessee, United States, 37232 收起 <<
NCT03695510	Head and Neck Neoplasms	Phase 2	Not yet recruiting	April 2021	Taiwan ... 展开 >> National Taiwan University Hospital Not yet recruiting Taipei, Taiwan, 100 Contact: Ruey-Long Hong, MD PhD +886-2-23123456 rlhong@ntu.edu.tw 收起 <<
NCT01523587	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	-
NCT01732640	-		Terminated(Slow accrual and hi... 展开 >>gh levels of toxicity lead to early termination.) 收起 <<	-	-
NCT01932229	NSCLC	Phase 2	Unknown	-	Israel ... 展开 >> Sheba Medical Center Recruiting Ramat Gat, Israel, 52621 Contact: Dina Vornstein Diana.Vorenshtein@sheba.health.gov.il Principal Investigator: Jair Bar, MD-PhD 收起 <<
NCT01836341	Non-small Cell Lung Cancer	Phase 1	Withdrawn	April 2015	-
NCT02020577	Neoplasms	Phase 1	Completed	-	France ... 展开 >> 1200.122.33001 Boehringer Ingelheim Investigational Site Villejuif Cedex, France Spain 1200.122.34001 Boehringer Ingelheim Investigational Site Madrid, Spain 收起 <<
NCT01003899	Carcinoma, Non-Small-Cell Lung	Phase 2	Completed	-	Korea, Republic of ... 展开 >> 1200.72.8201 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1200.72.8202 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1200.72.8203 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 收起 <<
NCT03652233	Recurrent Squamous Cell Carcin... 展开 >>oma of the Head or Neck Platinum- and Cetuximab-Refractory Squamous Cell Carcinoma of the Head or Neck Metastatic Squamous Cell Carcinoma of the Head or Neck Squamous Cell Carcinoma 收起 <<	Phase 1	Not yet recruiting	October 2022	United States, Tennessee ... 展开 >> Vanderbilt-Ingram Cancer Center Not yet recruiting Nashville, Tennessee, United States, 37232 Contact: Clinical Trials Information Program 800-811-8480 cip@vanderbilt.edu Principal Investigator: Mike Gibson, MD, PhD 收起 <<
NCT01003899	-		Completed	-	-
NCT01919879	Metastatic Colorectal Cancer	Phase 2	Completed	-	France ... 展开 >> Institute de Cancérologie de la Loire Nantes, France, 44805 收起 <<
NCT02216617	HNSCC	Phase 1	Completed	-	France ... 展开 >> ICM Val d'Aurelle, Montpellier Montpellier, France, 34298 收起 <<
NCT01861223	NSCLC	Phase 1 Phase 2	Unknown	May 2016	Korea, Republic of ... 展开 >> Samsung Medical Center Recruiting Seoul, Korea, Republic of Contact: Myung-Ju Ahn Sub-Investigator: Jong-Mu Sun 收起 <<
NCT02183883	Non-small Cell Lung Cancer	Phase 2	Recruiting	November 2023	United Kingdom ... 展开 >> Aberdeen Royal Infirmary (NHS Grampian) Recruiting Aberdeen, United Kingdom Principal Investigator: Gillian Price Heart of England NHS Foundation Trust Recruiting Birmingham, United Kingdom Principal Investigator: Shobhit Baijal Beatson West of Scotland Cancer Centre (NHS Greater Glasgow & Clyde) Recruiting Glasgow, United Kingdom Principal Investigator: Nicola Steele Barnet and Chase Farm Hospitals (Royal Free London NHS Foundation Trust) Recruiting London Borough Of Barnet, United Kingdom Principal Investigator: Tanya Ahmad University College London Hospitals NHS Foundation Trust Recruiting London, United Kingdom, NW1 2BU Principal Investigator: Martin Forster Cr Uk & Ucl Ctc Active, not recruiting London, United Kingdom, W1T 4TJ The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom Principal Investigator: Matthew Krebs 收起 <<
NCT02020577	-		Completed	-	-
NCT00748709	-		Terminated	-	-
NCT02780687	Urologic Neoplasms	Phase 2	Recruiting	March 30, 2020	France ... 展开 >> INS Bergonié Recruiting Bordeaux, France, 33076 CTR Léon Bérard Recruiting Lyon, France, 69373 INS Cancérologie du Gard Recruiting Nîmes, France, 30029 HOP Saint-Louis Recruiting Paris, France, 75010 HOP Cochin Recruiting Paris, France, 75014 HOP Européen G. Pompidou Recruiting Paris, France, 75015 HOP Foch Recruiting Suresnes, France, 92150 INS Claudius Regaud Recruiting Toulouse, France, 31059 INS Gustave Roussy Recruiting Villejuif, France, 94805 Italy Ospedale San Donato di Arezzo Recruiting Arezzo, Italy, 52100 A.O. San Camillo Forlanini Recruiting Roma, Italy, 00152 Spain Hospital Germans Trias i Pujol Recruiting Badalona, Spain, 08916 Hospital del Mar Recruiting Barcelona, Spain, 08003 Hospital Santa Creu i Sant Pau Recruiting Barcelona, Spain, 08025 Hospital Clínic de Barcelona Recruiting Barcelona, Spain, 08036 Hospital Vall d'Hebron Recruiting Barcelona, Spain, 08038 Hospital Universitario de Elche Recruiting Elche, Spain, 03202 Hospital Universitari de Girona Doctor Josep Trueta Recruiting Girona, Spain, 17007 Hospital Duran i Reynals Recruiting L'Hospitalet de Llobregat, Spain, 08908 Hospital Universitario Lucus Augusti Recruiting Lugo, Spain, 27003 Hospital Ramón y Cajal Recruiting Madrid, Spain, 28034 Hospital Clínico San Carlos Recruiting Madrid, Spain, 28040 Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Hospital La Paz Recruiting Madrid, Spain, 28046 CIO Clara Campal Recruiting Madrid, Spain, 28050 Hospital Son Espases Recruiting Palma de Mallorca, Spain, 07010 CS Parc Taulí Recruiting Sabadell, Spain, 08208 Hospital Virgen Macarena Recruiting Sevilla, Spain, 41009 Hospital Virgen del Rocío Recruiting Sevilla, Spain, 41013 Instituto Valenciano de Oncología Recruiting Valencia, Spain, 46009 收起 <<
NCT01523587	-		Completed	-	-
NCT01325428	-		Completed	-	-
NCT01553942	Lung Cancer	Phase 2	Recruiting	December 2020	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Geoffrey Oxnard, MD 617-632-6049 goxnard@partners.org Principal Investigator: Geoffrey Oxnard, MD Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02215 Contact: Lecia V Sequist, MD MPH 617-724-4000 lvsequist@partners.org Principal Investigator: Lecia V Sequist, MD MPH 收起 <<
NCT02438722	Recurrent Non-Small Cell Lung ... 展开 >>Carcinoma Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 2 Phase 3	Active, not recruiting	February 2022	-
NCT02450656	Colorectal Neoplasms ... 展开 >> Gastrointestinal Neoplasms Pancreatic Neoplasms Carcinoma, Non-Small-Cell Lung 收起 <<	Phase 1 Phase 2	Recruiting	December 2019	Netherlands ... 展开 >> UMC St. Radboud Nijmegen Recruiting Nijmegen, Gelderland, Netherlands, 6525GA Contact: Carla ML van Herpen, MD, PhD +31243610353 Carla.vanHerpen@radboudumc.nl Principal Investigator: Carla ML van Herpen, MD, PhD Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: F Opdam, MD, PhD Principal Investigator: F Opdam, MD, PhD 收起 <<
NCT00748709	Neoplasms	Phase 2	Terminated	-	United States, California ... 展开 >> 1200.26.3 Boehringer Ingelheim Investigational Site Los Angeles, California, United States United States, Colorado 1200.26.11 Boehringer Ingelheim Investigational Site Denver, Colorado, United States United States, Indiana 1200.26.9 Boehringer Ingelheim Investigational Site Indianapolis, Indiana, United States United States, Massachusetts 1200.26.1 Boehringer Ingelheim Investigational Site Boston, Massachusetts, United States United States, Nevada 1200.26.13 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States United States, New York 1200.26.4 Boehringer Ingelheim Investigational Site Albany, New York, United States 1200.26.2 Boehringer Ingelheim Investigational Site New York, New York, United States United States, Ohio 1200.26.7 Boehringer Ingelheim Investigational Site Kettering, Ohio, United States United States, Texas 1200.26.12 Boehringer Ingelheim Investigational Site Dallas, Texas, United States 1200.26.8 Boehringer Ingelheim Investigational Site Tyler, Texas, United States United States, Virginia 1200.26.6 Boehringer Ingelheim Investigational Site Norfolk, Virginia, United States United States, Washington 1200.26.10 Boehringer Ingelheim Investigational Site Vancouver, Washington, United States Taiwan 1200.26.88603 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1200.26.88601 Boehringer Ingelheim Investigational Site Taipei, Taiwan 1200.26.88602 Boehringer Ingelheim Investigational Site Tao-Yuan, Taiwan 收起 <<
NCT01074177	Non-small Cell Lung Cancer ... 展开 >> EGFR Mutations 收起 <<	Not Applicable	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT01074177	-		Completed	-	-
NCT01325428	Breast Neoplasms	Phase 2	Completed	-	United States, California ... 展开 >> 1200.89.10001 Boehringer Ingelheim Investigational Site Los Angeles, California, United States United States, North Carolina 1200.89.10005 Boehringer Ingelheim Investigational Site Durham, North Carolina, United States Australia, Victoria 1200.89.61002 Boehringer Ingelheim Investigational Site East Bentleigh, Victoria, Australia Australia, Western Australia 1200.89.61003 Boehringer Ingelheim Investigational Site Perth, Western Australia, Australia Hong Kong 1200.89.85201 Boehringer Ingelheim Investigational Site Hong Kong, Hong Kong Korea, Republic of 1200.89.82001 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of 1200.89.82002 Boehringer Ingelheim Investigational Site Seoul, Korea, Republic of Thailand 1200.89.66002 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.89.66004 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.89.66003 Boehringer Ingelheim Investigational Site Chiangmai, Thailand 1200.89.66001 Boehringer Ingelheim Investigational Site Hat-Yai, Songkhla, Thailand Tunisia 1200.89.21601 Boehringer Ingelheim Investigational Site Ariana, Tunisia 1200.89.21602 Boehringer Ingelheim Investigational Site Sousse, Tunisia United Kingdom 1200.89.44002 Boehringer Ingelheim Investigational Site Bournemouth, United Kingdom 1200.89.44001 Boehringer Ingelheim Investigational Site London, United Kingdom 1200.89.44003 Boehringer Ingelheim Investigational Site London, United Kingdom 收起 <<
NCT01214616	Neoplasms	Phase 1	Completed	-	Japan ... 展开 >> 1200.84.003 Boehringer Ingelheim Investigational Site Chuo-ku, Osaka, Osaka, Japan 1200.84.004 Boehringer Ingelheim Investigational Site Kashiwa, Chiba, Japan 1200.84.001 Boehringer Ingelheim Investigational Site Nagoya, Aichi, Japan 1200.84.002 Boehringer Ingelheim Investigational Site Sakyo-ku, Kyoto, Kyoto, Japan 收起 <<
NCT02716311	Non Small Cell Lung Cancer	Phase 2	Recruiting	January 2020	France ... 展开 >> Centre Hospitalier du Pays d'Aix Not yet recruiting Aix-en-Provence, France Contact: Stéphanie MARTINEZ contact@ifct.fr Clinique de L'Europe Not yet recruiting Amiens, France Contact: Olivier CARRE, Dr Angers - CHU Recruiting Angers, France Contact: José Hureaux, Dr Principal Investigator: José Hureaux, Dr Annecy - CH Recruiting Annecy, France, 74374 Contact: Chantal DECROISETTE, Dr Bordeaux - Institut Bergonié Not yet recruiting Bordeaux, France Contact: Sylvestre LE MOULEC, Dr contact@ifct.fr Principal Investigator: LE MOULEC Sylvestre, Dr Bordeaux - Polyclinique Nord Recruiting Bordeaux, France Contact: Nadine DOHOLLOU, Dr contact@ifct.fr Principal Investigator: Nadine DOHOLLOU, Dr Boulogne - Ambroise Paré Recruiting Boulogne-Billancourt, France Contact: Etienne GIROUX-LEPRIEUR, MD Principal Investigator: Etienne GIROUX-LEPRIEUR, MD Clermont-Ferrand - CHU Not yet recruiting Clermont-Ferrand, France Contact: Patrick MERLE, MD Principal Investigator: Patrick MERLE, MD CH Recruiting Colmar, France Contact: Lionel MOREAU contact@ifct.fr CHRU Grenoble Recruiting Grenoble, France Contact: Denis MORO-SIBILOT contact@ifct.fr Centre Hospitalier - Pneumologie Recruiting Le Mans, France, 72000 Contact: Olivier Molinier, Dr CHRU de Lille Recruiting Lille, France Contact: Alexis CORTOT, Pr contact@ifct.fr Lille - Polyclinique de la Louvière Not yet recruiting Lille, France Contact: Benjamin HURET, Dr contact@ifct.fr Principal Investigator: Benjamin HURET, Dr Lyon - Hôpital Privé Jean Mermoz Not yet recruiting Lyon, France Contact: Pierre Bombaron, MD contact@ifct.fr Principal Investigator: Pierre BOMBARON, MD Institut Paoli Calmette Recruiting Marseille, France Contact: Anne MADROSZYK, Dr Montpellier - GCS Centre de Cancérologie du Grand Montpellier Not yet recruiting Montpellier, France Contact: Catherine Becht, Dr Principal Investigator: Catherine Becht, Dr CH de Mulhouse Recruiting Mulhouse, France Contact: Didier DEBIEUVRE contact@ifct.fr Nantes - ICO René Gauducheau Recruiting Nantes, France Contact: Judith RAIMBOURG, Dr contact@ifct.fr Principal Investigator: Judith RAIMBOURG, Dr Nevers - CH Not yet recruiting Nevers, France, 58033 Contact: Dominique Herman, Dr Centre Antoine Lacassagne Recruiting Nice, France Contact: Josiane OTTO, MD contact@ifct.fr Orléans - Hôpital de la Source Recruiting Orléans, France Contact: Hugues MOREL, Dr contact@ifct.fr Principal Investigator: Hugues MOREL, Dr AP-HP Hopital Tenon - Pneumologie Recruiting Paris, France, 75020 Contact: Jacques Cadranel, Pr +33.1.56.01.65.31 contact@ifct.fr Principal Investigator: Jacques Cadranel, pr Paris - APHP Bichat Not yet recruiting Paris, France Contact: Valérie Gounant, Dr contact@ifct.fr Principal Investigator: Valérie Gounant, Dr Paris - APHP Saint-Louis Recruiting Paris, France Contact: Ludovic DOUCET, MD contact@ifct.fr Principal Investigator: Ludovic DOUCET, MD Pau - CH Recruiting Pau, France, 64046 Contact: Aldo RENAULT, Dr contact@ifct.fr Pontoise - CH Not yet recruiting Pontoise, France Contact: Cécile DURAND-MATRINGE, MD contact@ifct.fr Principal Investigator: Cécile DURAND-MATRINGE, MD Centre Hospitalier Recruiting Saint-Quentin, France Contact: Isabelle RAULT, MD contact@ifct.fr Nouvel Hopital Civil - Pneumologie Recruiting Strasbourg, France, 63000 Contact: Charlotte Leduc, Dr Principal Investigator: Charlotte Leduc, Dr Centre Hospitalier Intercommunal Recruiting Toulon, France Contact: Clarisse AUDIGIER-VALETTE, Dr HIA Saint Anne Recruiting Toulon, France Contact: Henri BERARD, Dr contact@ifct.fr Tours - CHU Not yet recruiting Tours, France, 37000 Contact: Eric Pichon, Dr contact@ifct.fr CH de Villefranche - Pneumologie Recruiting Villefranche, France Contact: Luc ODIER contact@ifct.fr Principal Investigator: Luc ODIER Villeneuve d'Ascq - Hôpital Privé Not yet recruiting Villeneuve-d'Ascq, France Contact: Benjamin HURET, MD Principal Investigator: Benjamin HURET, MD 收起 <<
NCT01214616	-		Completed	-	-
NCT03370770	-		Completed	-	Austria ... 展开 >> Otto-Wagner Hospital Vienna, Austria, 1140 收起 <<
NCT02191891	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	Japan ... 展开 >> National Hospital Organization Kyushu Cancer Center Fukuoka, Fukuoka, Japan, 811-1395 Korea, Republic of Chungbuk National University Hospital Cheongju, Korea, Republic of, 361-771 Severance Hospital, Yonsei University Health System Seoul, Korea, Republic of, 120-752 Samsung Medical Center Seoul, Korea, Republic of, 135-710 Asan Medical Center Seoul, Korea, Republic of, 138-736 Singapore National Cancer Centre Singapore, Singapore, 169610 Taiwan Chang Gung Memorial Hospital Chiayi Chiayi, Taiwan, 613 Kaohsiung Chang Gung Memorial Hospital Kaohsiung, Taiwan, 83301 NCKUH Tainan, Taiwan, 704 National Taiwan University Hospital Taipei, Taiwan, 100 收起 <<
NCT02470065	Non Small Cell Lung Cancer	Phase 2	Suspended(Study never started)	January 2021	-
NCT02979977	Squamous Cell Cancers of the H... 展开 >>ead and Neck 收起 <<	Phase 2	Recruiting	January 2020	United States, Connecticut ... 展开 >> Yale Cancer Center Recruiting New Haven, Connecticut, United States, 06520-8028 Contact: Clinical Trials Office 203-785-5702 Principal Investigator: Aarti Bhatia, MD United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital Not yet recruiting Baltimore, Maryland, United States, 21287 Contact: Hyunseok Kang, MD, MPH United States, Pennsylvania Fox Chase Cancer Center Not yet recruiting Philadelphia, Pennsylvania, United States, 19111 Contact: Jessica Bauman, MD 收起 <<
NCT02451553	Advanced Malignant Solid Neopl... 展开 >>asm Bile Duct Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Pancreatic Carcinoma Stage III Pancreatic Cancer AJCC v6 and v7 Stage IVA Pancreatic Cancer Stage IVB Pancreatic Cancer 收起 <<	Phase 1	Recruiting	-	United States, Indiana ... 展开 >> Indiana University/Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Sandra Wilson 317-274-3512 slhooper@iu.edu Principal Investigator: Safi Shahda United States, Washington Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Elena G. Chiorean 206-288-6248 gchiorea@uw.edu Principal Investigator: Elena G. Chiorean 收起 <<
NCT02876081	SMALL CELL LUNG CARCINOMA	Phase 2	Withdrawn(medical decision)	December 2018	France ... 展开 >> Groupe Hospitalier Paris Saint Joseph Paris, Ile-de-France, France, 75014 收起 <<
NCT01480141	Lung Cancer	Phase 2	Withdrawn(PI left MUSC, no pat... 展开 >>ient enrollments) 收起 <<	-	United States, South Carolina ... 展开 >> Medical University of South Carolina Charleston, South Carolina, United States, 29425 收起 <<
NCT02975141	Metastatic Pancreatic Cancer	Phase 1	Active, not recruiting	June 2019	Germany ... 展开 >> Ludwig-Maximilians - University of Munich Munich, Germany, 81377 收起 <<
NCT01721525	Head and Neck Cancer ... 展开 >> Squamous Cell Cancer 收起 <<	Phase 1	Completed	-	United States, New Jersey ... 展开 >> Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge, New Jersey, United States, 07939 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 收起 <<
NCT01814553	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	United States, California ... 展开 >> 1200.167.01009 Boehringer Ingelheim Investigational Site Santa Rosa, California, United States United States, Florida 1200.167.01020 Boehringer Ingelheim Investigational Site Orlando, Florida, United States 1200.167.01018 Boehringer Ingelheim Investigational Site Port St. Lucie, Florida, United States 1200.167.01012 Boehringer Ingelheim Investigational Site St. Petersburg, Florida, United States United States, Illinois 1200.167.01007 Boehringer Ingelheim Investigational Site Skokie, Illinois, United States 1200.167.01008 Boehringer Ingelheim Investigational Site Skokie, Illinois, United States United States, New Jersey 1200.167.01001 Boehringer Ingelheim Investigational Site Morristown, New Jersey, United States United States, Oregon 1200.167.01014 Boehringer Ingelheim Investigational Site Corvallis, Oregon, United States United States, Tennessee 1200.167.01002 Boehringer Ingelheim Investigational Site Chattanooga, Tennessee, United States 1200.167.01006 Boehringer Ingelheim Investigational Site Chattanooga, Tennessee, United States 1200.167.01005 Boehringer Ingelheim Investigational Site Nashville, Tennessee, United States United States, Virginia 1200.167.01003 Boehringer Ingelheim Investigational Site Richmond, Virginia, United States 收起 <<
NCT01999985	Lung Cancer N... 展开 >>on-small Cell Lung Cancer (NSCLC) 收起 <<	Phase 1	Active, not recruiting	March 2019	United States, Florida ... 展开 >> H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 收起 <<
NCT01531764	Carcinoma Breast Stage IV	Phase 2	Terminated(The recruitment was... 展开 >> discontinued because of failure to meet expected enrolment goals) 收起 <<	-	Germany ... 展开 >> Klinikum St. Marien Amberg Amberg, Bayern, Germany, 92224 Hämato-Onkologische Schwerpunktpraxis München, Bayern, Germany, 80638 Caritas-Krankenhaus, Onkologisches Zentrum Regensburg Regenburg, Bayern, Germany, 93053 Gynäkologische Praxis Hildesheim, Niedersachsen, Germany, 31134 Schwerpunktpraxis für Hämatologie und Onkologie Bottrop, Nordrhein-Westfalen, Germany, 46236 Universitätsklinikum Frauenklinik Düsseldorf Düsseldorf, Nordrhein-Westfalen, Germany, 40225 Otto-von-Guericke-Universität Frauenklinik Magdeburg Magdeburg, Sachsen-Anhalt, Germany, 39108 Klinikum Chemnitz gGmbH Chemnitz, Sachsen, Germany, 09116 Praxisklinik Krebsheilkunde für Frauen / Brustzentrum Berlin, Germany, 10367 Onkologisches Zentrum Süd, Vivantes Tumorzentrum Berlin, Germany, 12351 Internistische Praxisgemeinschaft Eppendorf Hamburg, Germany, 20249 OncoResearch Lerchenfled UG Hamburg, Germany, 22081 收起 <<
NCT01466660	Lung Neoplasms	Phase 2	Active, not recruiting	October 16, 2018	-
NCT01466660	-		Active, not recruiting	-	-
NCT02271906	Lung Cancer	Phase 2	Terminated(Poor Accrual)	-	United States, Texas ... 展开 >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 收起 <<
NCT01743365	Gastric Cancer ... 展开 >> Gastroesophageal Junction Cancer 收起 <<	Phase 2	Active, not recruiting	June 2019	Greece ... 展开 >> 2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital Athens, Greece, 11522 Dept of Medical Oncology, 251 Air Force Hospital Athens, Greece, 11525 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio" Athens, Greece, 11527 Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra" Athens, Greece, 11528 Division of Oncology, 2nd Dept of Internal Medicine, University Hospital "Attikon" Athens, Greece, 12462 2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital Athens, Greece, 14564 3rd Dept of Medical Oncology, Hygeia Hospital Athens, Greece, 15123 1st Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 2nd Dept of Medical Oncology, Metropolitan Hospital Athens, Greece, 18547 Dept of Medical Oncology, University Hospital of Heraklion Heraklion, Greece, 71110 Dept of Medical Oncology, Ioannina University Hospital Ioannina, Greece, 45110 Division of Oncology, Dept of Internal Medicine, University Hospital of Patras Patras, Greece, 26504 Dept of Medical Oncology, Papageorgiou General Hospital Thessaloniki, Greece, 56429 Dept of Medical Oncology, Thermi Clinic S.A Thessaloniki, Greece, 57001 收起 <<
NCT01783587	Squamous Cell Carcinoma of the... 展开 >> Head and Neck 收起 <<	Phase 1	Active, not recruiting	February 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 收起 <<
NCT01415011	Carcinoma, Non-Small-Cell Lung	Phase 2	Active, not recruiting	September 2018	United Kingdom ... 展开 >> Royal Bournemouth Hospital Bournemouth, United Kingdom Beatson West of Scotland Cancer Centre Glasgow, United Kingdom James Paget University Hospital Great Yarmouth, United Kingdom East Kent Hospitals Kent, United Kingdom Maidstone Hospital Kent, United Kingdom St James's University Hospital Leeds, United Kingdom The Royal Marsden Hospitals London Borough of Sutton, United Kingdom Barnet & Chase Farm Hospitals London, United Kingdom Charing Cross Hospital London, United Kingdom Guy's Hospital London, United Kingdom University College Hospital London, United Kingdom Musgrove Park Hospital Somerset, United Kingdom King's Mill Hospital Sutton in Ashfield, United Kingdom Weston General Hospital Weston Super Mare, United Kingdom York Hospital York, United Kingdom 收起 <<
NCT01853826	Carcinoma, Non-Small-Cell Lung	Phase 3	Active, not recruiting	March 31, 2019	-
NCT01542437	Non-Small Cell Lung Cancer ... 展开 >> EGFR HER-2 收起 <<	Phase 2	Active, not recruiting	June 2017	Mexico ... 展开 >> National Cancer Institute of Mexico Mexico city, Distrito Federal, Mexico, 14080 收起 <<
NCT03727724	Carcinoma, Non-Small-Cell Lung	Phase 2	Active, not recruiting	May 2021	Netherlands ... 展开 >> Antoni van Leeuwenhoek Amsterdam, North-Holland, Netherlands, 1066 CX VU Medical Center Amsterdam, Netherlands, 1007 MB University Medical Center Groningen Groningen, Netherlands, 9713 GZ Maastricht UMC+ Maastricht, Netherlands, 6229 HX 收起 <<
NCT02044380	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	Canada, Ontario ... 展开 >> Boehringer Ingelheim Investigational Site Barrie, Ontario, Canada Boehringer Ingelheim Investigational Site London, Ontario, Canada Boehringer Ingelheim Investigational Site Newmarket, Ontario, Canada Boehringer Ingelheim Investigational Site Toronto, Ontario, Canada Canada, Quebec Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada 收起 <<
NCT01538381	Carcinoma, Squamous Cell of He... 展开 >>ad and Neck 收起 <<	Phase 2	Completed	-	Belgium ... 展开 >> Institut Jules Bordet Brussels, Belgium, 1000 Cliniques Universitaires St. Luc Brussels, Belgium, 1200 U.Z. Leuven - Campus Gasthuisberg Leuven, Belgium, 3000 Italy Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Milano, Italy, 20133 收起 <<
NCT01320280	Refractory Cancer	Phase 2	Completed	-	Germany ... 展开 >> University Medical Center Hamburg-Eppendorf Hamburg, Germany, 20246 收起 <<
NCT01746251	Non Small Cell Lung Cancer	Phase 2	Active, not recruiting	August 2019	United States, California ... 展开 >> Stanford University Palo Alto, California, United States, 94304 United States, Massachusetts Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Massachusetts General Hospital Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan Kettering New York, New York, United States, 10065 收起 <<
NCT02747953	Non-small Cell Lung Cancer	Phase 2	Completed	-	-
NCT02208843	Carcinoma, Non-Small-Cell Lung	Phase 4	Completed	-	Egypt ... 展开 >> 1200.217.2201 Boehringer Ingelheim Investigational Site Alexandria, Egypt 1200.217.2202 Boehringer Ingelheim Investigational Site Cairo, Egypt 1200.217.2203 Boehringer Ingelheim Investigational Site Cairo, Egypt Malaysia 1200.217.6001 Boehringer Ingelheim Investigational Site Nilai, Malaysia Philippines 1200.217.6301 Boehringer Ingelheim Investigational Site Baguio City, Philippines 1200.217.6303 Boehringer Ingelheim Investigational Site Taguig, Philippines Poland 1200.217.4803 Boehringer Ingelheim Investigational Site Gdansk, Poland 1200.217.4805 Boehringer Ingelheim Investigational Site Szczecin-Zdunowo, Poland 1200.217.4801 Boehringer Ingelheim Investigational Site Warsaw, Poland Romania 1200.217.4004 Boehringer Ingelheim Investigational Site Braila, Romania 1200.217.4002 Boehringer Ingelheim Investigational Site Bucharest, Romania 1200.217.4005 Boehringer Ingelheim Investigational Site Craiova, Romania 1200.217.4003 Boehringer Ingelheim Investigational Site Iasi, Romania Serbia 1200.217.3801 Boehringer Ingelheim Investigational Site Belgrade, Serbia 1200.217.3802 Boehringer Ingelheim Investigational Site Belgrade, Serbia 1200.217.3804 Boehringer Ingelheim Investigational Site Kragujevac, Serbia 1200.217.3803 Boehringer Ingelheim Investigational Site Sremska Kamenica, Serbia Thailand 1200.217.6601 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.217.6603 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.217.6604 Boehringer Ingelheim Investigational Site Bangkok, Thailand 1200.217.6602 Boehringer Ingelheim Investigational Site Songkhla, Thailand 收起 <<
NCT02044380	-		Completed	-	-
NCT02096718	-		Completed	-	-
NCT02096718	Renal Insufficiency	Phase 1	Completed	-	Germany ... 展开 >> 1200.216.1 Boehringer Ingelheim Investigational Site Kiel, Germany 收起 <<
NCT01814553	-		Completed	-	-
NCT01824823	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 2	Active, not recruiting	December 2020	-
NCT01824823	-		Active, not recruiting	-	-
NCT02629523	Lung Neoplasms ... 展开 >> EGFR Gene Mutation 收起 <<	Phase 2	Active, not recruiting	March 2019	Korea, Republic of ... 展开 >> Chonnam National University Hwasun Hospital Hwasun, Jeonnam, Korea, Republic of, 58128 收起 <<
NCT01953913	Carcinoma, Non-Small-Cell Lung	Phase 3	Completed	-	China ... 展开 >> 307 Hospital of PLA Beijing, China, 100071 Beijing Cancer Hospital Beijing, China, 100142 Chinese PLA General Hospital Beijing, China, 100853 Jilin Province Cancer Hospital Changchun, China Guangdong General Hospital Guangzhou, China, 510080 Zhejiang Cancer Hospital Hangzhou, China, 310022 Lin Yi Tumor Hospital Linyi, China, 276002 Jiangsu Cancer Hospital Nanjing, China, 210000 Shanghai Chest Hospital Shanghai, China, 200030 Fudan University Shanghai Cancer Center Shanghai, China, 200032 Shanghai Pulmonary Hospital Shanghai, China, 200433 Tianjin Medical University Cancer Institute and Hospital Tianjin, China, 300060 Hong Kong Queen Mary Hospital Hong Kong, Hong Kong Prince of Wales Hospital Shatin, Hong Kong India Vikram Hospital Bangalore, India, 560052 HCG Hospital Bengaluru, India, 560027 P VS Hospital Pvt Ltd Calicut, India, 673002 V S Hospital Chennai, India, 600031 Max Super Speciality Hospital, Delhi Delhi, India, 110092 Global Hospitals Hyderabad, India, 500004 Basavatarakam Indo - American Cancer Hospital & Research Ins Hyderabad, India, 500034 SEAROC Cancer Centre Jaipur, India, 302004 B. P. Poddar Hospital & Medial Research Ltd Kolkata,West Bengal, India, 700053 Asirvatham Multispeciality Hospital Madurai, India, 625 020 Curie Manavata Cancer Centre Maharashtra, India, 422 004 Shatabdi Superspeciality Hospital Maharashtra, India, 422005 Prince Aly Khan Hospital Mumbai, India, 400010 Ruby Hall Clinic Pune, India, 411001 Singapore National Cancer Centre Singapore, Singapore, 169610 Taiwan E-Da Hospital Kaohsiung, Taiwan, 824 NCKUH Tainan, Taiwan, 704 Tri-Service General Hospital Taipei, Taiwan, 11490 Chang-Gung Memorial Hospital, Linkou Taoyuan County, Taiwan, 333 收起 <<
NCT02501603	Gastric Cancer ... 展开 >> Gastroesophageal Junction Cancer 收起 <<	Phase 2	Recruiting	December 2018	Korea, Republic of ... 展开 >> Severance Hospital, Yonsei University Health System, Yonsei Cancer Center Recruiting Seoul, Korea, Republic of, 120-752 Contact: Hyosong Kim, M.D 82-2-2228-8124 hyosong77@yuhs.ac 收起 <<
NCT02122172	Distal Urethral Cancer ... 展开 >> Proximal Urethral Cancer Recurrent Bladder Cancer Recurrent Urethral Cancer Stage III Bladder Cancer Stage III Urethral Cancer Stage IV Bladder Cancer Stage IV Urethral Cancer Ureter Cancer 收起 <<	Phase 2	Recruiting	June 12, 2019	United States, Illinois ... 展开 >> University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Peter H. O'Donnell 773-702-7564 podonnel@medicine.bsd.uchicago.edu Principal Investigator: Peter H. O'Donnell Decatur Memorial Hospital Recruiting Decatur, Illinois, United States, 62526 Contact: James L. Wade 217-876-6600 JLWADE3@sbcglobal.net Principal Investigator: James L. Wade NorthShore University Health System Completed Evanston, Illinois, United States, 60201 收起 <<
NCT02491099	HER2/Neu+ Uterine Serous Carci... 展开 >>noma 收起 <<	Phase 2	Recruiting	June 2021	United States, Arizona ... 展开 >> University of Arizona Cancer Center Recruiting Tucson, Arizona, United States, 85724 Contact: Setsuko Chambers, M.D. 520-626-0950 schambers@uacc.arizona.edu Contact: Elizabeth Collins, BSHCA 520-694-9067 jenniecollins@email.arizona.edu United States, Connecticut Yale New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Alessandro D. Santin, M.D. 203-737-4450 alessandro.santin@yale.edu Contact: Lisa Baker, R.N. 203-785-6398 lisa.baker@yale.edu United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Whitfield Growdon, MD 617-724-4800 wgrowdon@partners.org Contact: Louisa Bauer, RN 617-643-5415 LJBAUER@mgh.harvard.edu Principal Investigator: Whitfield Growdon, MD 收起 <<
NCT02274012	HER-2 Positive Gastric Cancer ... 展开 >> Gastrooesophageal Cancer Esophageal Cancer 收起 <<	Phase 2	Withdrawn(Former PI left insti... 展开 >>tution and had plans to continue at another institution.) 收起 <<	-	-
NCT01522768	Esophageal Cancer ... 展开 >> Gastric Cancer 收起 <<	Phase 2	Recruiting	February 2019	United States, California ... 展开 >> University of Southern California Recruiting Los Angeles, California, United States, 90033 Contact: Syma Iqbal, MD 323-865-3907 Principal Investigator: Syma Iqbal, MD United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Janet Murphy, MD 617-724-5600 United States, New Jersey Memoral Sloan Kettering Basking Ridge Recruiting Basking Ridge, New Jersey, United States Contact: Yelena Janjigian, MD Principal Investigator: Yelena Janjigian, MD Memoral Sloan Kettering Monmouth Recruiting Middletown, New Jersey, United States, 07748 Contact: Yelena Janjigian, MD 646-888-4186 Memorial Sloan Kettering Bergen Recruiting Montvale, New Jersey, United States, 07645 Contact: Yelena Janjigian, MD 646-888-4186 United States, New York Memorial Sloan Kettering Commack Recruiting Commack, New York, United States, 11725 Contact: Yelena Janjigian, MD Principal Investigator: Yelena Janjigian, MD Memorial Sloan Kettering Westchester Recruiting Harrison, New York, United States, 10604 Contact: Yelena Janjigian, MD 646-888-4186 Memorial Sloan Kettering Cancer Center Recruiting New York, New York, United States, 10065 Contact: Yelena Janjigian, MD 646-888-4186 Contact: David Ilson, MD 646-888-4183 Principal Investigator: Yelena Janjigian, MD Memorial Sloan Kettering Rockville Centre Recruiting Rockville Centre, New York, United States Contact: Yelena Janjigian, MD Principal Investigator: Yelena Janjigian, MD 收起 <<
NCT02369484	NSCLC	Phase 2	Completed	-	Germany ... 展开 >> Universitätsklinikum Köln Köln, Germany Netherlands NKI-AVL Amsterdam, Netherlands Spain Vall d'Hebron University Hospital Barcelona, Spain Switzerland CHUV Lausanne, Switzerland USZ Zürich, Switzerland 收起 <<
NCT02364609	Recurrent Non-Small Cell Lung ... 展开 >>Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 1	Active, not recruiting	December 2018	United States, California ... 展开 >> University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 收起 <<
NCT02695290	-		Terminated	-	-
NCT02514174	Carcinoma, Non-Small-Cell Lung... 展开 >> ErbB Receptors 收起 <<	Phase 4	Active, not recruiting	December 18, 2018	United States, Arizona ... 展开 >> Mayo Clinic-Phoenix Scottsdale, Arizona, United States, 85250 United States, California Pacific Cancer Medical Center, Inc. Anaheim, California, United States, 92801 City of Hope Duarte, California, United States, 91010 Compassionate Care Research Group, Inc. at Compassionate Cancer Care Medical Group, Inc. Fountain Valley, California, United States, 92708 Los Angeles Hematology Oncology Medical Group Los Angeles, California, United States, 90017 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, Illinois Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 United States, Massachusetts Baystate Health D'Amour Center for Cancer Care Springfield, Massachusetts, United States, 01199 United States, New York Montefiore Medical Center Bronx, New York, United States, 10467 United States, Pennsylvania Lankenau Medical Center Wynnewood, Pennsylvania, United States, 19096 收起 <<
NCT02695290	Carcinoma, Non-Small-Cell Lung... 展开 >> ErbB Receptors 收起 <<	Phase 4	Terminated	-	United States, California ... 展开 >> 1200.208.10032 Boehringer Ingelheim Investigational Site Fountain Valley, California, United States 收起 <<
NCT03711422	Non-small Cell Lung Cancer ... 展开 >> Leptomeningeal Disease Central Nervous System Metastases 收起 <<	Phase 1	Not yet recruiting	September 30, 2020	-
NCT01427478	Head and Neck Squamous Cell Ca... 展开 >>rcinoma 收起 <<	Phase 3	Active, not recruiting	September 2021	France ... 展开 >> Centre Paul Papin Angers, France, 49933 Institut Sainte-Catherine Avignon, France, 84000 CHU Bordeaux - Hôpital Saint-André Bordeaux, France, 33075 Polyclinique de Bordeaux Nord Bordeaux, France, 33300 CHRU Brest - Hôpital Morvan Brest, France, 29609 Centre François Baclesse Caen, France, 14076 CHIC Créteil Créteil, France, 94010 Centre Guillaume le Conquérant Le Havre, France, 76600 Centre Hospitalier Bretagne Sud Lorient, France, 56100 Centre Léon Bérard Lyon, France, 69373 AP-HM La Timone Adultes Marseille, France, 13386 Cedex Centre Antoine Lacassagne Nice, France, 06189 CHU Poitiers Poitiers, France, 86021 Centre Eugène Marquis Rennes, France, 44229 Centre Henri Becquerel Rouen, France, 76038 Institut de Cancérologie de la Loire Saint Priest en Jarez, France, 42270 Institut de Cancérologie de l'Ouest Saint-Herblain, France, 44805 Pôle Hospitalier Mutualiste- Centre Etienne Dolet Saint-Nazaire, France, 44600 Strasbourg Oncologie Libérale Strasbourg, France, 67000 Hopitaux du Léman Thonon-les-bains, France, 74203 Clinique Pasteur Bâtiment l'Atrium Toulouse, France, 31076 Institut Claudius Regaud Toulouse, France, 71000 CHU TOURS (Hôpital Bretonneau) Tours, France, 37044 Centre de Radiothérapie Marie Curie Valence, France, 26000 Institut de Cancérologie de lorraine (ICL) Vandoeuvre-les-Nancy, France, 54519 cedex Institut Gustave Roussy Villejuif, France, 94805 收起 <<
NCT01415674	Carcinoma, Squamous Cell of He... 展开 >>ad and Neck 收起 <<	Phase 2	Completed	-	France ... 展开 >> CHU d'Angers Angers, France Institut de cancérologie de l'Ouest - Site Paul Papin Angers, France Centre François Baclesse Caen, France, 14000 Centre Léon Bérard Lyon, France, 69373 Institut de cancérologie de l'Ouest - Site René Gauducheau Nantes Saint-herblain, France Chu de Nantes Nantes, France Centre Antoine Lacassagne Nice, France, 06189 Institut Curie Paris, France, 75248 Institut Claudius Regaud Toulouse, France, 31052 Centre Alexis Vautrin Vandoeuvre les Nancy, France, 54511 Institut Gustave Roussy Villejuif, France, 94800 收起 <<
NCT02511847	Triple Negative Breast Cancer	Phase 2	Unknown	July 2017	Taiwan ... 展开 >> National Taiwan University Hospital Recruiting Taipei City, Taiwan, 110 Contact: Chiun-Sheng Huang 886-23123456 ext 65080 收起 <<
NCT02625168	Lung Cancer	Phase 2	Completed	-	Hong Kong ... 展开 >> Department of Clinical Oncology, Queen Mary Hospital Hong Kong, Hong Kong 收起 <<
NCT03486509	Squamous Cell Carcinoma	Phase 2	Not yet recruiting	July 1, 2020	-
NCT02423525	Brain Cancer	Phase 1	Recruiting	December 2020	United States, California ... 展开 >> John Wayne Cancer Institute Recruiting Santa Monica, California, United States, 90404 Contact: Jaya Gill, RN 310-582-7437 jaya.gill@providence.org Principal Investigator: Santosh Kesari, MD, PhD 收起 <<
NCT03083678	Chordoma	Phase 2	Recruiting	December 2019	Italy ... 展开 >> Istituto Nazionale dei Tumori: Fondazione IRCCS Not yet recruiting Milan, Italy Contact: S Stacchiotti, MD Netherlands Leiden University Medical Center Recruiting Leiden, Netherlands Contact: H Gelderblom, MD Prof United Kingdom University College London Hospital Not yet recruiting London, United Kingdom Contact: S Strauss, MD 收起 <<

(E/Z)-Afatinib {[allProObj[0].p_purity_real_show]}

(E/Z)-Afatinib 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

(E/Z)-Afatinib 质控信息

(E/Z)-Afatinib 生物活性

(E/Z)-Afatinib 细胞研究

(E/Z)-Afatinib 动物研究

(E/Z)-Afatinib 临床研究

(E/Z)-Afatinib 参考文献

(E/Z)-Afatinib 实验方案

(E/Z)-Afatinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

(E/Z)-Afatinib {[allProObj[0].p_purity_real_show]}

(E/Z)-Afatinib 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

(E/Z)-Afatinib 质控信息

(E/Z)-Afatinib 生物活性

(E/Z)-Afatinib 细胞研究

(E/Z)-Afatinib 动物研究

(E/Z)-Afatinib 临床研究

(E/Z)-Afatinib 参考文献

(E/Z)-Afatinib 实验方案

(E/Z)-Afatinib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

(E/Z)-Afatinib 纯度/质量文件产品仅供科研